In depth analysis of the HIV-specific CD8 T cell response in seropositives exposed to a mixed subtype epidemic by Geldmacher, Christof
  
 
 
 
In depth analysis of the HIV-specific CD8  
T cell response in seropositives exposed to a 
mixed subtype epidemic 
 
 
 
 
Dissertation 
zur Erlangung des Grades des  
Doktors der Naturwissenschaften 
der Naturwissenschaftlich-Technischen Fakultät III 
Chemie, Pharmazie, Bio- und Werkstoffwissenschaften 
der Universität des Saarlandes 
 
 
 
vorgelegt von 
 
Diplom Biologe 
Christof Geldmacher 
 
 
Saarbrücken 
2006 
 Tag des Kolloquiums: 28. April 2006 
 
Dekan:  Prof. Dr. Hegetschweiler 
 
Berichterstatter:  Prof. Dr. Meyerhans 
  Prof. Dr. Meese 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Dedicated to all the bar and sex workers of this planet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations 
 
aa amino acid 
Ag antigen 
AIDS aquired immune deficiency syndrome 
CCR5 chemokine receptor, co-receptor for HIV-1 
CXCR4 chemokine receptor, co-receptor for HIV-1 
CD   cluster of differentiation 
CEF   Cytomegalo virus, Eppstein Barr virus, Influenza virus 
CMV   Cytomegalo virus 
CPTA   4-[(1,4,8,11-tetraazacyclotetradec-1-yl)-methyl]benzoic acid 
   (=anti-coagulant) 
CRF   circulating recombinant form 
CTL   cytotoxic T lymphocyte 
DMSO  Dimethylsulfoxid 
dNTP   desoxy-nucleoside triphosphate 
EBV   Epstein-Barr virus 
ELISA   enzyme-linked immunosorbent assay 
ELISPOT  enzyme-linked immunospot assay 
Env   envelope protein 
FACS   "fluorescence activated cell sorting" 
FCS   fetal calf serum 
FITC   Fluoresceinisothiocyanat 
Fmoc   N-alpha-(9-fluorenylmethyloxycarbonyl)-amino acid 
FU   follow up 
Gag   group specific antigen 
GagR1R3  Gag regions aa001 to aa075 and aa248 to aa500 
Gag plus number number of overlapping 15mer peptide within gag 
GM-CSF  Granulocyte-Macrophage colony stimulating factor 
gp   glycoprotein 
H001-H605  sample ID of study subject 
HISIS   HIV superinfection study 
HIV human immunodeficiency virus 
HLA   human leukocyte antigen 
HPLC   high performance liquid chromatography 
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Nef negative factor, HIV accessory protein 
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p24 HIV capsid protein of 24 kd  
p15 HIV nucleocapsid proteins complexing viral RNA  
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PCR polymerase chain reaction 
QC quality control 
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RNA ribonucleic acid 
rpm rotations per minute 
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Introduction 
1.1 The Human Immunodeficiency Virus (HIV) 
HIV belongs to the family of Retroviridae. Together with other 
immunodeficiency viruses, such as the simian and feline immunodeficiency 
viruses, HIV belongs to the genus of lentiviruses. The name is derived from the 
Latin lentus, meaning slow, because of the gradual course of the diseases that 
these viruses cause. 
 
The closely related human immunodeficiency viruses HIV-1 and HIV-2 are the 
disease causing agents of the acquired immunodeficiency syndrome (AIDS). 
Worldwide around 40 million people are now infected with HIV with up to 5 
million new infections in the year 2005 (UNAIDS). AIDS is characterized by a 
profound decrease of CD4 T cells leading to an increased susceptibility a wide 
variety of opportunistic pathogens. Several bacterial and viral infections, such 
as Mycobacterium tuberculosis and human Herpes virus 8 (HHV-8), infections 
with fungi, such as Candida albicans, and infections with the protozoan 
Pneumocystis carinii can be indicative of AIDS. Frequent diagnoses of such 
infections in homosexual men in combination with low lymphocyte counts lead 
to the description of AIDS in 1981 (Gottlieb et al., 1981).The virus was first 
isolated from the lymph node of an AIDS patient in 1983 (Barre-Sinoussi et al., 
1983). The viral sequence was determined in 1985 (Barre-Sinoussi et al., 1983; 
Muesing et al., 1985; Ratner et al., 1985; Sanchez-Pescador et al., 1985; Wain-
Hobson et al., 1985) and since 1986 the name of the virus was changed from 
lymphadenopathy associated virus (LAV) to HIV (Coffin et al., 1986).  
 
1.1.1 Genome and replication of HIV 
HIV is a retrovirus with a genome of approximately 10kb of size (Ratner et al., 
1985; Wain-Hobson et al., 1985). Due to its 5’-Cap-structure and a 3’-
polyadenylation, the HIV genome closely resembles an eukaryotic mRNA. 
Characteristic for retroviruses, the genome contains direct repeats (R) on both 
ends and two unique sequences, one after the direct repeat at the 5’ end (U5), 
the other immediately preceding the direct repeat at the 3’ end (U3) (figure 
1.1). The genome consists of the three classical retrovirus open reading frames 
(ORF), the gag (group-specific antigen) ORF, the pol (polymerase) ORF and 
                                                                                                         Introduction
 2
the env (envelope) ORF. In addition to these, the HIV-1 genome contains genes 
encoding for the small accessory proteins Nef, Vif, Rev, Tat, Vpu, Vpr (Table 
1.1). The gag ORF encodes for the p17 matrix protein, the p24 capsid protein, 
the p7 nucleocapsid protein and the p6 link-protein. The pol ORF encodes for 
the viral enzymes reverse transcriptase, integrase and protease and the env ORF 
encodes for the viral glycoprotein gp160, which is cleaved inside the lumen of 
the Golgi-apparatus into functional gp41 and gp120 by the cellular furin-
protease. 
 
Tab. 1.1: Function and localization of small accessory proteins of 
HIV-1  
Gene product Localisation Function 
Tat  
("transactivator of 
transcription") 
• Binds to “RNA-trans-
activation response 
region” at the 5´-end of 
the proviral DNA 
• Regulates trans-activation of 
the transcription (Klotman 
et al., 1991) 
Rev  
("regulator of 
virion protein 
expression") 
• Binds to „rev responsive 
element“ in unspliced 
and singly spliced 
mRNA 
 
• Regulates switch from early 
to late gene expression 
• essential for expression of 
virion proteins  
• Binding causes translocation 
of these RNAs into 
cytoplasm (Hope and 
Pomerantz, 1995) 
Vif 
("virus infectivity 
factor") 
• inside the virion, inside 
the cytoplasm  and 
extracellular in cell 
culture supernatant of 
infected cells 
• binds to Apobec proteins and 
excludes them from 
incorporation  into virions 
(Mangeat et al., 2003) 
 
 
 
 
 
                                                                                                         Introduction
 3
Tab. 1.1: Function and localization of small accessory proteins of HIV-1  
Gene product Localisation Function 
Nef  
("negative 
regulatory factor") 
• is translated from 
multiply spliced 
mRNAs 
• membrane associated 
through myristoylation 
• increases viral replication 
• affects T cell activation 
• downregulates CD4 and 
MHC Class I molecules on 
surface of infected cells 
• protects infected cell from 
superinfection (Michel et al., 
2005) 
• downregulation of MHC 
Class I helps to evade the 
HIV-specific CD8 T cell 
response (Aiken et al., 1994; 
Collins et al., 1998; Garcia 
and Miller, 1991) 
• influences cell cycle 
machinery 
(Shaheduzzaman et al., 
2002) 
Vpr  
("viral protein R") 
• intracellular, mainly 
inside the nucleus (Lu et 
al., 1993), but also 
inside virion 
• participates in the nuclear 
import of the pre-integration 
complex (Heinzinger et al., 
1994) 
• influences cell cycle (Goh et 
al., 1998; He et al., 1995) 
• regulates NF-κB (Ayyavoo 
et al., 1997) 
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Tab. 1.1: Function and localization of small accessory proteins of HIV-1  
Gene product Localisation Function 
Vpu  
("viral protein U") 
• inside the cytoplasm • Degradation of CD4 inside 
ER and transport of HIV-1 
Env to the cell surface 
(Willey et al., 1992) 
• Assembly and release of 
virions from  the cell  
(Cohen et al., 1988; Strebel 
et al., 1988) 
 
 
Upon viral entry into host cells, the RNA genome is reverse transcribed into 
double-stranded DNA, which is subsequently integrated into the chromosome. 
The integrated viral genome, called proviral DNA, is flanked on both ends by 
long terminal repeats (LTR) made of U3, R and U5 (figure 1.1). The LTR 
contains cis-active elements that are important for the integration of the viral 
DNA into the host genome and for the transcription of the retroviral genome 
(Haseltine, 1991; Klotman et al., 1991; Steffy and Wong-Staal, 1991). 
 
Transcription of the viral genome is initiated upon activation of the host cell 
and depends on the presence of various cellular transcription factors. Most 
important are the transcription factors nuclear factor kappa B (NF-κB) and 
nuclear factor of activated T cells (NF-AT) that are expressed in activated CD4 
T cells (Kinoshita et al., 1997; Perkins et al., 1993). The cellular RNA 
polymerase II complex transcribes the proviral DNA. Early transcripts are 
multiply spliced and code for the regulatory proteins Tat, Rev and Nef. Tat is a 
potent transcriptional regulator and functions as an elongation factor that 
enhances the transcription of the proviral DNA about 100-fold. Rev promotes 
the export of unspliced or partially spliced RNAs. Later in the replication cycle 
and with increasing concentration of Rev, unspliced and partially spliced RNA 
transcripts of the structural proteins and the viral enzymes are translocated 
efficiently from the nucleus into the cytoplasm.  
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The gag and pol ORFs are transcribed into one mRNA. During translation a 
shift in the ribosomal reading frame occurs with a frequency of around 5% in 
an uridine-rich region that is located upstream of the gag stop codon. This 
suppresses translational termination at the gag–pol border and decoding of the 
mRNA may proceed past the gag stop codon. Therefore about 20-fold more 
Gag precursor protein than the Gag/Pol fusion protein is being synthesized.  
 
The virion is formed at the plasma membrane by an ordered self-assembly of 
the viral structural proteins together with the genomic RNA. After closure of 
the spherical ribonucleoprotein shell, the immature virion is released from the 
cell and undergoes a functional and morphological maturation. During 
maturation the Gag precursor protein and the Gag/Pol fusion protein is cleaved 
into functional proteins by the viral protease. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Organization of the HIV-1 genome 
Besides the gag, pol and env ORFs that are characteristic for all retroviruses, 
the HIV genome contains additional regulatory genes. (Table 1.1) (according to 
Feinberg and Greene 1992) 
5' LTR 3' LTR
U3  R  U5
gag
pol
envvif
vpu
tat
rev
nef
vpr U3  R  U5
Cell genome Cell genome
                                                                                                         Introduction
 6
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2   Replication cycle of HIV 
1. HIV binds to CD4 and a cellular co-receptor on host cells and subsequently 
enters the cell after the viral membrane fuses with the cellular membrane. 2. 
Reverse Transcription (RT) of the 2 viral RNAs into 1 double stranded DNA.  
3. The pre-integration complex is transported into the nucleus and the viral 
DNA is integrated into the host cell chromosome. 4. Proviral gene expression 
and transcription of genomic viral RNAs (vRNA). 5. Virus self-assembly at the 
cellular membrane and viral budding. 6. Maturation of virion and infection of a 
new cell. 
 
 
The replication of HIV is coupled with a mutation rate of 2.5 x 10-5 per cycle 
per replication round. Responsible for this mutation rate is mainly the low-
fidelity reverse transcriptase (RTase). It lacks the proof reading mechanisms 
that is common for cellular DNA polymerases and produces “sequence errors” 
during reverse transcription of the genomic RNA into cDNA.   
 
 
 
 
 
1
2
3
4
5
entry
RT
integration
“Provirus”
RNA
DNA
budding
transcription
translation
vRNA
receptor
mature Virion immature
Virion
6 maturation
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1.1.2 The HIV virion 
The HIV virion is spherical and about 100nm in diameter. It has a lipid 
membrane, which is derived from the cellular membrane of the infected cell 
(Figure 1.2). Integrated into the virus envelope is the transmembrane 
glycoprotein gp41, which is non-covalently associated with the highly 
glycosylated protein gp120. Besides gp41, cellular membrane proteins are also 
inserted into the viral membrane.  Gp41 and gp120 both are highly variable. 
The latter interacts with the cellular receptor CD4 and, depending on the HIV 
strain-specific tropism, either with the cellular co-receptor CCR-5 or CXCR-4. 
Subsequently gp41 initiates fusion of the viral membrane with the cellular 
membrane. 
 
All the capsid and nucleocapsid proteins are derived from the Gag precursor 
protein. The matrix protein p17 is associated with the inner surface of the viral 
membrane. P17 is important for incorporation of the envelope protein into 
mature virions (Yu et al., 1992). It also assists with the transport of the pre-
integration complex and acts in targeting this complex into the nucleus in 
quiescent, non-dividing cells (Bukrinsky et al., 1993; von Schwedler et al., 
1994). Furthermore, because of its affinity for the cytoplasmic domain of gp41, 
p17 also plays an important role in positioning viral cores at the budding sites 
inside the infected cell (Dorfman et al., 1994; Yu et al., 1992). 
 
The capsid of the lentiviruses is conical in shape and consists of the capsid 
protein p24. Domains mainly at the C-terminus of p24 are essential for the 
assembly of the spherical ribonucleoprotein shell (Zhang et al., 1996), while 
the N-terminal region is required for the formation of the mature, cone shaped 
core. The middle region of p24 contains the “major homology motif”, which is 
well conserved among different retroviruses and is important for the formation 
of infectious virions (Mammano et al., 1994). The smaller proteins p7 and p6 
are derived from p15. The nucleocapsid protein p7 binds directly to the viral 
genome whereas p6 links the viral membrane to the viral capsid. Besides the 
structural proteins the HIV virion contains the viral enzymes reverse 
transcriptase, integrase and protease and the viral genome, two copies of 
single-(+) stranded RNA molecules.  
                                                                                                         Introduction
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Figure 1.3.  Schematic structure of an HIV virion. Inside the virion there is 
the conical capsid made of the capsid protein p24. The capsid contains the 
enzymes reverse transcriptase, integrase and protease, cellular tRNAs and the 
viral genome, two copies of single-(+) stranded RNA molecules, which are 
complexed by the nucleocapsid protein p7. The capsid is surrounded by a lipid 
membrane. The viral glycoprotein gp41 and host cell surface proteins are 
integrated into the viral membrane. Gp120 is non-covalently bound to gp41. 
The matrix protein p17 and the link-protein p6 are associated with the inner 
surface of the viral membrane – the latter connects the viral capsid to the 
membrane. 
 
 
1.1.3 Phylogeny and evolution of HIV 
HIV-1 and HIV-2 are closely related to the simian immunodeficiency viruses 
(SIV). HIV-2 is related to the SIVsm from the monkey sooty mangaby and 
HIV-1 to the SIVcpz from the chimpanzee. HIV-2 mainly occurs in Western 
Africa. HIV-1, which contributes to most of the pandemic, can be subdivided 
into the three groups, group M (main), group O (outlier) group N (new). For 
these groups, independent zoonotic transmission events must have occurred, as 
each of these groups is more closely related to a particular SIVcpz strain than 
among themselves. Fig.1.4 shows the phylogenetic relationship of SIVcpz to 
HIV-1 group M. HIV-1 group O and group N appear to be rare and are found 
tRNA
2x (+)Genomic RNA
Nucleocapsid
(p7)
Capsid
(p24)
Protease
Reverse Transcriptase
Integrase
Lipid membrane
Glycoprotein (gp120)
Glycoprotein (gp41)
Matrix (p17)
host protein
Link-protein 
(p6)
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almost exclusively in the Central-West African countries Equatorial Guinea 
and Cameroon. Group M spread most efficiently into the human population 
and is the cause of the HIV pandemic. Based on phylogenetic analysis of a 
large number of HIV-1 sequences collected over the years and the fact that the 
first identified HIV group M infection case dates back to 1959 (Isolate ZR.59) 
it is believed that the founder of the HIV-1 group M crossed from chimpanzee 
to human early during the 20th century (Korber et al., 2000). 
 
HIV-1 is amongst the most genetically variable human pathogen. 
Geographically defined epidemics can be characterized by the dominance of 9 
distinct genetic subtypes of HIV-1 group M (subtypes A, B, C, D, F, G, H, J 
and K). The phylogenetic analysis of the predominant group M subtypes is 
shown in figure 1.4. Of the 9 different subtypes, only 4 of the 9 subtypes 
contribute to 90% of the HIV pandemic (Kijak and McCutchan, 2005). 
Subtype C is responsible for more than 50% of world wide infections, followed 
by subtype B, subtype A and subtype D. The global distribution of HIV-1 
subtypes is shown in figure 1.5. Parameters contributing to this global pattern 
of subtype distribution remain speculative. The highest diversity of HIV-1 
subtypes and recombinants is seen in the central African countries, which is 
likely to relate to the long time period since the start of the HIV epidemic in 
that particular region.  
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Figure 1.4.  Phylogenetic analysis of predominant subtypes of HIV-1 group 
M and SIVCPZ. The phylogenetic tree shows the genetic distances and 
relationships between subtypes A, B, C, D and G of HIV-1 group M, SIVCPZ 
and HIV-1 group O. 
 
1.1.4 Multiple infection and recombination 
It is known that an individual can be infected by more than one HIV strain 
(Altfeld et al., 2002; Hoelscher et al., 2002) that subsequently can give rise to 
recombinant viruses. The basis for the generation of these recombinant forms 
of HIV is the infection of the same cell with more than one HIV-1 variant. Jung 
et al demonstrated that one infected cell can habour multiple genetically 
distinct proviruses (Jung et al., 2002). As a consequence, two RNA strands that 
are derived from two different proviruses have the opportunity to assort at the 
packaging stage. Upon infection of a new host cell, recombination of the two 
genomic RNA molecules occurs via the mechanism of strand switching of the 
reverse transcriptase during the process of reverse transcription (An and 
Telesnitsky, 2002; Jetzt et al., 2000). Within an infected individual carrying 
multiple HIV subtypes, ongoing inter-strain recombination may contribute to a 
strong fluctuation of many different molecular HIV-1 forms over time 
(Gerhardt et al., 2005; McCutchan et al., 2005). 
                                                                                                         Introduction
 11
 
A growing number of HIV-1 recombinant forms has been identified within the 
last few years. Some epidemics are characterized by so-called circulating 
recombinant forms (CRFs) or by unique recombinant forms (URFs). A CRF is 
a recombinant HIV strain that has achieved to spread into a larger population. 
There are two recombinant forms of global importance. CRF01_AE 
predominates in Southern Asia and CRF02_AG in some Western and Central 
African countries (Fig 1.5). At present, there are at least 16 circulating 
recombinant forms (CRFs) and many unique recombinant forms (URFs) 
described (http:// www.hiv.lanl.gov/content/hiv-db/CRFs/ CRFs.html). A high 
proportion of URFs is exclusively seen in the context of an epidemic with 
mixed HIV subtypes and is indicative for a relatively high frequency of 
multiply infected individuals. This phenomenon is characteristic for the 
regional HIV-1 epidemics of Eastern and Central African countries. 
 
 
 
 
Figure 1.5. Regional epidemic patterns of HIV-1 subtypes and 
recombinant forms. Shown is the global distribution of subtypes and 
recombinant forms of HIV-1. 
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1.2 The human immune system 
The meaning of the word “immunity” refers to the protection from an 
infectious agent. All cells, molecules and organs that contribute to this 
immunity are summarized in the term “immune system”. The immune system 
can be subdivided into two branches that closely interact with each other: The 
innate immune system includes phagocytic cells such as neutrophiles and 
macrophages, natural killer cells (NK cells) that – upon activation - are an early 
source of IFN gamma (IFNγ) and soluble molecules such as the components of 
the complement system. The components of the innate immune system have a 
relatively limited capacity to recognize microbe-specific structural features, but 
they serve as an important first and early line of defence against many 
pathogens (Janeway et al., 2003).   
 
The specific immune response is initiated by professional antigen-presenting 
cells (APC), such as dendritic cells (DCs), macrophages and B cells that can 
take up antigen. APCs are characterized by high level expression of major 
histocompatibility complex (MHC) and co-stimulatory molecules on their cell 
surface, that are essential for the activation of T cells. Especially DCs play a 
central role in the initiation of the adaptive immune response. Most of the 
common pathogen entry routes such as the skin and mucosal surfaces are 
interspersed with DCs. After antigen encounter, DCs can take up antigen in the 
periphery and migrate to the draining lymph node, where they serve as a potent 
activator for the T cell response. The adaptive immune response relies on 
clonal expansion of antigen-specific B cells and T cells. Both of these cell 
types express a highly specific antigen receptor on their cell surface and can 
differentiate into “memory cells”. Memory cells are long lived and are not 
depleted after antigen is cleared. Therefore they can contribute to a long lasting 
immunity to an infection with the same pathogen. 
 
The high specificity of the B and T cell antigen receptor is based on somatic 
gene rearrangements of highly variable gene segments that code for the antigen 
binding site of the antigen receptor, namely the B cell receptor (BCR) and the 
T cell receptor (TCR). The mechanism of somatic gene rearrangement is 
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unique to lymphocyte development and has evolved with the vertebrates 
(Janeway et al., 2003).  
 
1.2.1 The humoral immune response 
The humoral immune response to infection involves the production of 
pathogen-specific antibodies by activated B cells, the binding of antibodies to 
the pathogen and direct neutralization or elimination of the pathogen by 
phagocytic cells or the complement system. B cells express an antigen specific 
membrane associated BCR that is secreted upon antigen binding and activation 
of the B cell. The secreted form of the BCR is referred to as an antibody. 
Depending on its specificity, the BCR can bind proteins, carbohydrates, DNA 
or various other molecules. In contrast to pathogen-specific CD8 T cells, B 
cells do not need antigen presentation in the context of the MHC, and therefore 
are less restricted in their capacity to recognize antigens. However, they do 
require “help” by pathogen specific CD4 T cells to produce antibodies of high 
affinity and efficiency. An effective humoral immune response is the main 
determinant of protective immunity after vaccination and most of the antiviral 
vaccines that are currently available are based on the induction of a strong and 
efficient antibody response (Janeway et al., 2003).  
 
1.2.2 Antigen presentation by MHC class I molecules  
After a virus has used the cells’s biosynthetic machinery to express its viral 
proteins, these proteins are partly degraded by the proteasome inside the 
cytoplasm. The proteasome cleavage products are peptides of 8-11 amino acids 
length that are actively transported by the transporter proteins – TAP1 and 
TAP2 - into the lumen of the endoplasmatic reticulum, where they are loaded 
onto MHC class I molecules (Niedermann et al., 1999). The MHC-peptide 
complex is then transported to the cell surface and presented to CD8 T cells. 
All nucleated cells are capable to express MHC class I molecules and its 
expression is upregulated by various cytokines. Specific CD8 T cells that 
recognize antigenic peptides in the context of MHC class I molecules are 
activated and differentiate into armed effector cells.  
MHC class II molecules are almost exclusively expressed on the surface of 
professional antigen presenting cells (APCs) and present antigenic peptides to 
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CD4 T cells. Antigens are engulfed by APCs and degraded inside the 
endosomal compartment. Antigenic peptides are then loaded onto the MHC 
class II molecules and translocated to the cell surface (Janeway et al., 2003).   
 
The genes encoding for the MHC molecules are highly polygenic. There are 
more than 500 MHC class I and app. 500 MHC class II variant genes 
described. These variant genes are referred to as alleles and the human MHC 
molecules are referred to as Human leukocyte antigens (HLA).  Polygeny 
differs between the 3 HLA class I genes A, B and C. The HLA-B genes are the 
most variable with more than 380 different alleles described by the year 2001. 
HLA-C alleles are the least polygenic with 93 alleles described by 2001 
(Janeway et al., 2003). 
 
The protein products of individual HLA alleles can differ from one another by 
up to 20 amino acids, making each variant protein quite distinct. The 
polymorphism is largely confined to amino acids lining the peptide binding 
groove and affects the peptide binding properties of a HLA molecule. 
Particular amino acid residues anchor the peptide into pockets within the 
peptide binding groove. Stable binding of a peptide to a particular HLA 
molecule depends on these anchor residues and the amino acids lining the 
peptide binding groove. Anchor residues do not need to be identical for all 
peptides that bind to the same HLA molecule, but are always related – 
hydrophobic, polar, charged or aromatic. The set of anchor residues binding to 
a given HLA molecule is called a sequence motif (Janeway et al., 2003). For 
example HLA-B0702 predominantly presents peptides that bear the 
hydrophobic amino acids proline or valine in position 2 and a leucine at the C-
terminus. HLA-B1510 presents peptides with a histidin in position 2 and a 
leucine residue at C-terminus (http://www.hiv.lanl.gov/content/immunology 
motif_scan/ motif_ scan). Individual differences in the expressed HLA alleles 
therefore can have a profound effect on how individuals can deal with a 
particular pathogen. As a consequence, the specificity of T cell recognition 
within an individual is largely dependent on the set of HLA alleles expressed.  
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On a population level the MHC polymorphism has one important advantage, 
because not all individuals in a population will be equally susceptible to a 
given pathogen and its spread can therefore be limited. At an evolutionary time 
scale exposure to certain pathogens can select for particular HLA alleles within 
a given population. For example the HLA-B53 allele has been shown to be 
associated with recovery a potentially lethal form of Malaria (Hill et al., 1992). 
This allele is very common in West African population, where Malaria is 
endemic and rare elsewhere. Curiously, HLA-alleles also influence the body 
scent of an individual and can affect reproductive behaviour (Singh, 2001; 
Yamazaki et al., 1979). Potential partners with different HLA-alleles to oneself 
are preferred as mating partners. These findings indicate the importance of the 
HLA gene locus for human evolution.  
 
1.2.3 The cellular immune response 
In contrast to B cells, T cells only recognize antigen after presentation through 
MHC molecules. T cells express the antigen-specific T cell receptor complex 
that consists of the T cell receptor (TCR), CD3 and either co-receptor CD4 or 
CD8. CD4 and CD8 bind to conserved regions of the MHC Class II and Class I 
molecules respectively. The activation of naïve T cells requires not only 
recognition of MHC presented peptides by the TCR, but also the presence of 
the co-stimulatory molecules CD80 and CD86 that are expressed on the surface 
of professional antigen presenting cells (Janeway et al., 2003).  
 
CD4 T cells, also called T helper cells (TH cells), are central to the function of 
the immune system as they are specialized to provide “help” to other cells. 
CD4 T cell help is essential for the generation of an effective antibody 
response, for the activation of macrophages and the maintenance of an 
effective CTL response. The role of CD4 T cells has intensively been studied 
in a CD4 knock-out mouse model. Upon experimental infection with the 
LCMV virus, CD4 knock-out mice have an impaired antibody response and a 
decreased frequency of antigen-specific memory CD8 T cells (Rahemtulla et 
al., 1991; von Herrath et al., 1996). In HIV infected humans, the important role 
of CD4 T cells is also exemplified. Once most of the CD4 T cells are 
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eliminated during the HIV infection, individuals are highly susceptible to a 
whole range of opportunistic infections. 
CD4 T cells can be subdivided according to their cytokine secretion pattern. 
TH1 cells predominantly secrete IFNγ, Tumor Necrosis Factor alpha (TNFα), 
interleukin 2 (IL-2) and granulocyte macrophage colony stimulating factor 
(GM-CSF), whereas TH2 cells predominantly secrete IL-4, IL-5, IL-6 and IL-
10. As a consequence both subsets differ in their respective function. TH1 cells 
are mainly specialized to activate macrophages infected with intracellular 
pathogens such as Mycobacteria or Leishmania species (Paulnock et al., 1992). 
TH2 cells predominantly help B cells in the induction of an efficient antibody 
response and can be important in the downregulation of inflammatory 
responses by secretion of IL-10. Differentiation into either TH1 or TH2 cells is 
largely dependent on the cytokine microenviroment during the inductive phase 
of T cell priming (Janeway et al., 2003). 
 
The function of CD8 T cells is to kill cells infected with intracellular 
pathogens. They are important to eliminate pathogens that are not susceptible 
to elimination by antibodies due to their intracellular location. Upon encounter 
with an infected cell the lytic granules move towards the cell-cell contact area 
and release the effector molecules perforin and granzymes. Perforin inserts and 
forms pores into the target cell membrane, whereas granzymes enter through 
these pores and induce apoptosis of the target cell. For this reason CD8 T cells 
are often referred to as cytotoxic T lymphocytes (CTL). Antigen specific CD8 
T cells can also secrete various cytokines such as IFNγ and TNFα and various 
other cytokines. IFNγ directly inhibits replication of some viruses and 
increases expression of MHC class I molecules and other molecules involved 
in peptide loading of the MHC class I molecules (Pamer and Cresswell, 1998).  
 
1.2.4 The HIV-specific immune response 
Detection of HIV-specific antibodies after seroconversion is the method of 
choice to diagnose an HIV infection. Most infected individuals mount a strong 
humoral immune response against a variety of HIV-1 proteins in the course of 
their infection. Antibodies targeting epitopes within the highly variable viral 
envelope protein gp120 may have the capacity to efficiently neutralize the 
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virus. However, one typical characteristic of HIV-1 is that it rapidly escapes 
these antibody responses by the continuous generation of mutant viruses 
(Fenyo et al., 1996). Simultaneously, this high antigenic variability of the viral 
envelope glycoproteins also contributes to the poor cross-neutralizing capacity 
for different HIV-1 strains. Preferential destruction of HIV-specific CD4 T-
helper cells by HIV (Douek et al., 2002) may further decrease efficiency of the 
HIV-specific humoral immune response. 
 
Several observations underline the importance of the humoral immune 
response in HIV infection. Antibodies that activate the classical pathway of the 
complement system may in part contribute to the control of plasma viremia 
after acute infection (Aasa-Chapman et al., 2005). Passive transfer of 
neutralizing antibodies against a highly pathogenic SHIV strain can protect 
Rhesus macaques from infection (Aasa-Chapman et al., 2005; Mascola et al., 
1999; Mascola et al., 2000). Furthermore immunization with Env encoding 
DNA and recombinant Env protein resulted in sterile immunity of monkeys 
against SHIV-HXBc2 challenge (Letvin et al., 1997). A recent study in humans 
has demonstrated a delay of HIV-1 rebound after cessation of antiretroviral 
therapy through passive transfer of human neutralizing antibodies (Trkola et 
al., 2005). 
 
Unfortunately the induction of broadly cross-reactive antibodies with the 
capacity to neutralize a diversity of primary virus isolates has not been 
achieved until today. Some potentially neutralization epitopes are poorly 
immunogenic (Liang et al., 1999; Zwick et al., 2001), others are masked by 
neighbouring N-linked glycans (Reitter et al., 1998). One highly conserved 
antigenic region, a conserved co-receptor binding site, is exposed only for a 
very limited time period during infection of a new host cell. Antibodies 
directed against this conserved co-receptor binding site have been found to 
neutralize a wide range of HIV-1 primary isolates and even HIV-2 primary 
isolates (Shaw G., Talk at the AIDS Vaccine Conference Lausanne 2004). In 
this regard attempts to achieve sterilizing immunity by vaccination still hold 
some promises.  
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It is generally accepted that HLA Class I restricted CD8 T cell responses 
largely contribute to the control of HIV-1 replication in infected individuals. 
The appearance of HIV-specific CD8 T cells is temporally associated with the 
decline of plasma viremia shortly after acute infection (Borrow et al., 1994; 
Koup et al., 1994). During the chronic phase of infection, an inverse correlation 
between the frequency of CD8 T cells specific for (two) HLA-A2 restricted 
epitopes and the viral load was found (Ogg et al., 1998). Perhaps, the most 
conclusive data about the protective role of CD8 T cells comes from the SIV-
rhesus macaque model, in which depletion of CD8 T cells leads to a transient 
rise in SIV plasma viremia and loss of CD4 T cells until the CD8 T cell subset 
recovers (Jin et al., 1999; Schmitz et al., 1999). However, the parameters 
determining efficient control of viral replication had still to be defined. With 
improvements of the technology to rapidly and accurately characterize CD8+ T 
cell responses in HIV-1 seropositive individuals, many new T cell epitopes 
have been detected, permitting identification of immunodominant regions 
across the whole HIV proteome. This resulted in the establishment of Gag and 
Nef as the most frequently targeted HIV-1 proteins contributing to more than 
half of the total HIV-specific T cell response in most individuals (Addo et al., 
2003; Frahm et al., 2004). That the Gag-specific CD8 T cell response may play 
a special role in slowing down progression to AIDS was first shown in 1995 
(Riviere et al., 1995) and numerous more recent studies supported this finding 
(Edwards et al., 2002; Masemola et al., 2004; Novitsky et al., 2003; Ramduth 
et al., 2005). In contrast, other studies have not found a correlation between the 
Gag-specific T cell response and the viral load (Addo et al., 2003; Betts et al., 
2001). Surprisingly, Nef- or Env-specific CD8 T cell responses have never 
been associated with efficient viral control or even found to be positively 
correlating with a high viral load, indicating that CD8 T cells of different 
specificity may differ in their respective antiviral efficiency (Betts et al., 2001).  
 
The CD8 T cell specificities found in one individual are dependent on the HLA 
Class I background. The identification of HLA class I alleles that contribute to 
a slow HIV disease progression has been vigorously pursued over the years. 
Particular HLA class I alleles, such as B57 (Altfeld et al., 2003), B5801 and 
B4201 (Kiepiela et al., 2004) are associated with slower disease progression, 
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while other HLA class I alleles, such as B5802, B4501 and B1510 (Kiepiela et 
al., 2004) appear to correlate with a higher viral load. Direct evidence of how 
“protective” HLA alleles may exert this effect is still lacking, although it has 
been shown that within a given population frequent HLA alleles can influence 
the predominant amino acid sequences found in targeted HIV epitopes 
(Kiepiela et al., 2004; McMichael and Klenerman, 2002).  
 
HIV amino acid sequence variability plays an important role in both HIV-
specific humoral and cell-mediated immune responses. The viral Env and Nef 
proteins are both very variable with up to 30% sequence differences, whereas 
Gag and Pol are more conserved between different HIV-1 isolates (<10% 
sequence differences). To complicate matters for the HIV-specific immune 
response, even within an HIV-1 infected individual, the HIV mutant spectrum, 
or “quasispecies” can reach a divergence of 10% (Meyerhans et al., 1989; 
Plikat et al., 1997). Sequence variability within CD8 T cell epitopes varies and 
HIV-1 can escape pressure from the CD8 T cell response by mutating targeted 
epitope sequences. Nonetheless, some antigenic protein regions are well 
conserved because of their particular importance for viral fitness. Amino acid 
point mutations within these epitopes may lead to a severely decreased 
replicative capacity of the virus (Goulder and Watkins, 2004). To identify such 
CD8 T cell epitopes or protein regions with a high density of such epitopes 
may contribute to HIV vaccine design. The whole extent to which HIV genetic 
diversity impacts T cell epitope recognition is not completely established. It 
was only very recently that peptides representing multiple subtypes have been 
used to screen for multiple subtype reactivity (Barugahare et al., 2005; Coplan 
et al., 2005). It now appears that sequence variability does not always directly 
predict the degree of cross-subtype CD8 T cell recognition, although the level 
of cross-subtype responses is substantial for HIV-1 Nef and strong, but 
somewhat lower,  for the Gag protein (Coplan et al., 2005). 
 
1.3 Pathogenesis of HIV 
HIV and the related SIV cause a depletion of CD4 T cells in infected 
individuals. CD4 T cells are very important regulators of the immune system. 
They “help” B cells to produce high affinity antibodies, they activate APCs and 
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they play a role in the maintenance of memory CD8 T cells (von Herrath et al., 
1996). The respective depletion of CD4 T cells during an HIV infection is the 
cause for a whole range of virus-induced immune defects called AIDS.  
 
Infection with HIV generally occurs after transfer of body fluids such as blood, 
semen or vaginal secretion from an infected person. Unprotected sex is the 
most common mode of transmission, followed by perinatal transmission from 
an HIV-infected mother to the child. Transmission through breast feeding also 
accounts for a high number of HIV infections in young children - especially in 
highly affected populations of Sub-Saharan Africa. Besides these, contact with 
contaminated blood or blood products can cause infection with HIV. 
 
During the initial infection, the virus is either introduced directly into the blood 
system or through lesions of the mucous membranes. Another mechanism how 
the virus crosses the mucosal barrier is transcytosis (Bomsel H., 1997). The 
epithelial cells of the mucosal surfaces lining the reproduction tract are 
interspersed with a dense network of dendritic cells. The virus attaches to DCs 
via a protein called DC-SIGN (Geijtenbeek et al., 2000). Binding to DC-SIGN 
stabilizes the otherwise fragile virus and upon activation the DC migrates to the 
draining lymph node, where this “hitch-hiking” virus encounters a large 
population of CD4 T cells (Geijtenbeek and van Kooyk, 2003). After initial 
replication, the virus disseminates quickly into the blood stream and into other 
primary lymphatic organs. The lymphatic system is the primary place of HIV 
replication and serves as an important viral reservoir.  
 
HIV primarily infects and destroys the memory CD4 T cells (Chun et al., 1997; 
Spina et al., 1997). Most of the bodies’ memory CD4 T cells are found in the 
gut associated lymphatic tissues (GALTs) – predominantly in the lamina 
propria. The gut is a primary entry site for food and water borne pathogens and 
hence the GALTs are among the largest and most dynamic of all primary 
lymphatic organs. To prevent pathogens from entering the body, the lamina 
propria harbours a high level of the activated memory CD4 T cells. These cells 
co-express CD4 and the HIV co-receptor CCR5 (Veazey et al., 2000). This 
activated CCR5 positive memory subset of CD4 T cells is easily infected by 
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HIV and contributes to the high level of early virion production. GALTs 
therefore are viewed as the most important site of active viral replication and T 
cell depletion during acute infection.  
 
The acute HIV disease is often characterized by flu-like symptoms, which 
usually disappear after viral replication is brought under control by the HIV-
specific immune response. Plasma viral load drops to the “viral set point” and 
simultaneously CD4 T cell levels rise although not quite to the levels seen 
before HIV infection (Fig.1.6). The plasma viral load at the viral set point 
correlates well with the time from infection to the onset of AIDS symptoms 
(Mellors et al., 1996).  
 
The dynamic of the CD4 T cell depletion during the acute infection has been 
studied extensively in the SIV-Rhesus macaque model and resembles the 
dynamic of HIV infection in humans. However, it should be considered that 
SIV is usually introduced intravenously with a high number of virions. The 
extent of memory CD4 T cell destruction is immense during the acute phase of 
infection. After inoculation SIV eliminates around half of the host’s memory 
CD4 T cells within 2 weeks (Mattapallil et al., 2005). In contrast naïve CD4 T 
cells are virtually unsusceptible to SIV infection (Mattapallil et al., 2005). 
Interestingly, the majority of infected cells during the acute infection were 
resting CD4 T cells and infected cells were not restricted to the gut associated 
lymphoid tissue (Mattapallil et al., 2005). Although these infected resting 
memory CD4 T cells produce less virions than activated dividing cells, they 
serve as a major viral reservoir. Therefore the acute phase of infection is likely 
to play a key role in SIV and HIV pathogenesis. The mechanisms contributing 
to this rapid destruction of the memory CD4 T cell subset are not well 
understood, but both viral induced cytolysis and CTL mediated mechanisms 
could explain this dramatic CD4 T cell loss (Johnson and Kaur, 2005; 
Mattapallil et al., 2005).  
 
A gradual decline of CD4 T cells marks the chronic phase of HIV infection. As 
a consequence of the continuously falling CD4 T cell counts, a variety of 
opportunistic infections and cellular malignancies can occur in the infected 
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individual (Fig. 1.6). The asymptomatic chronic phase of infection can vary 
tremendously between infected individuals, but usually lasts for 5-15 years and 
is marked by a high turn-over rate of virions (Pantaleo et al., 1993). 109 to 1010 
new virions are generated and eliminated each day and it is thought that 99% of 
the new virions are generated by newly infected CD4 T cells (Ho et al., 1995; 
Perelson et al., 1996; Wei et al., 1995). However, most destroyed CD4 T cells 
are replenished by newly generated cells. During chronic infection, the plasma 
viremia is commonly at comparatively low levels (Piatak, Jr. et al., 1993) and 
the frequency of infected CD4 T cells is fewer than 1 in 1000 (Haase, 1999). 
 
The final AIDS phase of HIV infection is characterized by profound changes of 
primary lymphoid organ architecture. The network of follicular dendritic cells 
is destroyed and the germinal centers are exterminated. The lymphoid organ 
function collapses and with it the control of HIV replication and other 
opportunistic infections. Primary HIV strains isolated during the AIDS phase 
often display an altered cellular tropism. During acute and early infection HIV 
mostly binds to the target cell through the cellular co-receptor CCR5, while 
HIV isolates from later stages of infection often bind to the co-receptor CXCR-
4 (Connor et al., 1997; Scarlatti et al., 1997). In contrast to the CCR5-tropic 
strains, primary isolates of CXCR4-tropic strains replicate rapidly in cell 
culture, contribute to high virion titers and mediate the formation of a high 
number of syncytial forming cells. The appearance of CXCR-4 tropism is 
associated with a bad prognosis (Scarlatti et al., 1997). It is not completely 
understood, what mechanisms contribute to this changing tropism and 
virulence, but it has been shown in a Rhesus macaque-SHIVDH12R model that 
infection of Rhesus macaques with this CXCR-4 tropic SHIV strain results in a 
massive loss of naïve CD4 T cells (Nishimura et al., 2005). In human HIV 
infection, sequence differences in the V3 region of gp120 correlate with this 
shift in cellular tropism (Liu et al., 1990; O'Brien et al., 1990).  
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                    acute phase      chronic phase  AIDS phase  
 
Figure 1.6. HIV and CD4 T cell levels over the course of an untreated 
HIV-1 infection. The acute phase of an HIV infection are often characterized 
by an acute influenza-like viral illness with high titers of virus in the blood. An 
adaptive immune response follows, which controls viral replication, but does 
not eradicate the virus. At the same time, CD4 T cell levels are largely 
restored. The chronic phase is asymptomatic in most HIV infected individuals 
and usually lasts for several years with a continuous decline of CD4 T cells. 
Opportunistic diseases and other symptoms become more frequent during the 
AIDS phase as the CD4 T cell count falls, starting at around 200-400 cells/µl.  
 
1.4 The HIV superinfection study  
The HIV Superinfection Study (HISIS) is an open cohort study conducted in 
Mbeya region in south-western Tanzania. The HISIS cohort consists of 600 
high risk female bar-workers aged 18-35 years, who were recruited from 14 
high-transmission areas within Mbeya region. The HIV prevalence at the 
beginning of the HISIS study in 2001 was app. 70%. The HIV incidence was 
high during the first year of the study but dropped subsequently (Hoffmann et 
al., 2004). The study was designed to investigate various aspects of HIV 
infection: I) the molecular characterization of the regional HIV-1 epidemic, II) 
the identification of subjects with multiple infection of different HIV subtypes, 
III) the evolution of viral quasispecies in individuals infected with multiple 
HIV-1 strains, IV) the analysis of the HIV-specific cellular immune response in 
the context of a multi-subtype epidemic and V) the identification of co-factors 
and parameters that increase the risk of HIV infection such as other sexually 
transmitted diseases and sexual behaviour.  To enable a detailed analysis of the 
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infecting HIV strains, the cohort was followed up for a total of 4.3 years with 
17 follow ups in 3-month intervals. 
 
1.5 Objectives 
Increasing evidence supports an important role for the HLA class I restricted 
CD8 T cell response in the control of HIV viral replication in vivo. 
Consequently, most of the current vaccine strategies are based at least in part 
on the induction of a strong HIV-specific CD8 T cell response. However, it is 
not completely understood why some HIV-infected individuals appear to 
control viral replication over extended time periods, while others progress 
rapidly despite a strong HIV-specific CD8 T cell response.  
 
The anti-viral efficiency of the HIV-specific CD8 T cell response may be 
influenced by two important parameters, I) the HLA Class I background of the 
infected individual and II) the genetic variability of the virus. Hence advances 
in HIV vaccine design will require not only a better understanding of the 
immune responses that control this retrovirus but also a better understanding of 
these responses in the context of individual host genetics and an understanding 
of the implications of HIV diversity. 
 
In this work three central questions concerning the HIV-specific CD8 T cell 
response were addressed:  
 
1.) How do favourable HLA class I alleles contribute to the HIV-specific CD8 
T cell response? What determines the anti-viral efficiency of the CD8 T cell 
response in general?  
 
2.) What is the degree of HIV cross-subtype recognition within antigenic 
regions that are frequently recognized by HIV-specific CD8 T cells? 
 
3.) Does the increased diversity of viral “quasispecies” within multiply HIV-1 
infected individuals affect the HIV-specific CD8 T cell response? 
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To answer these questions, the HIV-specific CD8 T cell response was studied 
in the context of a mixed HIV subtype epidemic. The HIV-specific responses 
against Gag, Nef and Env were mapped to individual peptides that were 
representative of the locally occurring HIV subtypes A, C and D. 
Simultaneously, the genetic diversity of infecting HIV-1 strains was 
characterized and the HLA class I background of the study subjects was 
determined for each of the study subjects. 
A number of fundamental insights into the HIV-specific T cell response could 
be derived from the analysed data. 
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2. Materials and methods 
 
2.1 Chemical reagents 
 
Brefeldin A     Sigma, Deisenhofen 
DMSO     Sigma, Deisenhofen 
EDTA      Becton Dickinson, Heidelberg 
FACS Lysing Solution   Becton Dickinson, Heidelberg 
FBS      Gibco, Invitrogen, Karlsruhe 
Ficoll-Hypaque    Sigma, Deisenhofen 
Gentomycin (50mg/ml)   Sigma, Deisenhofen 
HEPES     Gibco, Invitrogen, Karlsruhe  
Iso-Propyl alcohol    BMLS-Dar Es Salaam 
L-glutamine     Gibco, Invitrogen, Karlsruhe  
Nova-Red Substrate    Vector, Burlingame, California 
PBS      Sigma, Deisenhofen 
Penicillin/Streptomycin   Gibco, Invitrogen, Karlsruhe 
PHA      Sigma, Deisenhofen 
RPMI 1640     Gibco, Invitrogen, Karlsruhe 
SEB      Sigma, Deisenhofen 
Streptavidin-horseradish peroxidase  Pharmingen, San Diego 
Trypane blue     Sigma, Deisenhofen   
Tween-20     Sigma, Deisenhofen 
 
 
2.2 Characteristics of study subjects 
600 female bar workers were enrolled in the Mbeyan region, Tanzania between 
September and November 2000 for a prospective HIV Superinfection Study 
(HISIS) within the Mbeya Medical Research Programme (MMRP). After 
giving informed consent, each participant provided blood samples at enrolment 
and every three months for a four years period. During the study, all 
participants received health care that included treatment of all acute infectious 
diseases, of sexually transmitted diseases, and since 2003, cotrimoxazole 
prophylaxis for opportunistic infections for women with CD4+ T-cell counts 
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below 200. Since September 2004, all women with low CD4 counts have 
access to antiretroviral treatment within the Southern Highland Care and 
Treatment Programme. The HIV status of all study subjects was determined 
using two diagnostic HIV enzyme-linked immunoassays (ELISA), Enzygnost® 
Anti HIV1/2 Plus, Dade Behring, Liederbach, Germany and Determine™ HIV 
1/2, Abbott, Wiesbaden, Germany). Discordant results were resolved using a 
Western Blot assay (Genelabs Diagnostics, Geneva, Switzerland). The genetic 
subtypes of HIV-1 were determined with a fluorescent genotyping assay, 
MHAacd (see 2.7). In April 2003, fifty-six of the HIV-1 positive participants 
were enrolled into the HISIS-CTL study, and HIV specific T-cell responses 
were measured for 4 consecutive follow ups (FU). Study subjects who did not 
belong to the HISIS cohort, were chosen from two cohorts: One cohort that 
evaluated the HIV prevalence and circulating subtypes (CODE study) in the 
Mbeya region and the other belonged to a pre-study for evaluation of surrogate 
markers for tuberculosis activity. After giving informed consent each subject 
was screened for HIV infection and their immune response to HIV was 
assessed. 
 
2.2.1 Determination of CD4 T cell counts by immunophenotyping 
 
The determination of the CD4 T cell count from whole blood was based on 
fluorescent activated cell sorting (FACS). FACS allows the characterization of 
single cells depends on hydrodynamic focussing. During this process the cells 
are accelerated and pass the laser light in the flow cell. Simultaneously the size 
and the granularity of the cells are determined by measuring the forward and 
the sideward scattered light, respectively and allows differentiation of 
lymphocytes from monocytes and granulocytes. 
 
Immunophenotyping is the identification of cell surface antigens characteristic 
of subsets of leucocytes utilizing fluorescence-labeled monoclonal antibodies. 
Fluorescence-labeled antibodies bind to the leucocyte subset-specific surface 
antigens. The fluorescence of the chromophore is being activated by a laser and 
the emitted light is detected with an optical system. During this work a 
FACSCalibur (Becton Dickinson, Heidelberg) was used enabling measurement 
of 4 different chromophores simultaneously. 
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Procedure 
 
The determination of CD4 cell counts was performed using the MultiTEST 
IMK Kit with TruCOUNT Tubes (Becton Dickinson, Heidelberg). Each 
TruCOUNT tube includes a defined number of small particles that are detected 
via fluorescence activation. This allows direct quantification of the cell 
concentration in the blood sample. The MultiSET software provides a lab-
report with multi-colored dot plots and a physician’s report, which shows the 
patient data and the normal reference ranges. The results are reported as the 
percentage of positive cells per lymphocyte population or as an “absolute 
count” which shows up the number of positive cells per microliter of blood. 
Briefly, 50µl of whole blood, collected into CPTA tubes, was added to the 
TruCount tubes. 10 µl of MultiTEST antibody mix (CD3-FITC-labeled; CD8-
PE-labeled; CD45-PerCP-labeled; CD4-APC-labeled) was added, the tubes 
gently vortexed and incubated for 15 minutes in the dark at room temperature. 
To lyse the red blood cells, 450 µl of FACS lysing solution (Becton Dickinson, 
Heidelberg) was added, the sample gently vortexed and incubated for 15min in 
the dark. The acquisition and analysis was performed using the FACSCalibur 
together with the MultiSET software.  
 
2.2.2 Determination of plasma viral load 
Plasma viral load was determined with a COBAS Amplicor TM analyzer 
(Roche Diagnostics, Penzberg, Germany) that allows complete 
automatization of the amplification and detection steps of the Polymerase 
Chain Reaction testing process. The principle of this assay is briefly described 
in the following. As a first step, HIV-1 RNA is isolated from plasma by lysis of 
virus particles with a chaotropic agent followed by precipitation of the RNA 
with alcohol. The HIV-1 RNA then serves as a template for the amplification 
of a sequence of 142 bases located in a highly conserved region of the HIV-1 
gag gene. The nucleotide sequence of the biotinylated primers has been 
optimized to yield equivalent amplification of Group M subtypes of HIV-1. 
This region is reversely transcribed into DNA and subsequently amplified by 
the enzyme Thermus thermophilus DNA polymerase. As a quantitative 
standard, a known amount of control RNA (Quantitative Standard target RNA, 
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included in the Amplicor 1.5 reagent kit, Roche Diagnostics) is treated in the 
same way. The amplicon is then chemically denatured to form single stranded 
DNA. The denatured amplicon preparations are added to designated wells of a 
microwell plate coated with HIV-1 specific oligonucleotide probes and a series 
of 5-fold dilutions of the amplicons is made. The biotin-labeled HIV-1 
amplicons hybridize to the plate-bound HIV-1 specific probes and are captured 
onto the plate. This specific hybridization of the amplicons increases the 
overall specificity of the reaction. Following the hybridization reaction, the 
microwell plate is washed to remove unbound material and avidin-conjugated 
horseradish peroxidase (Av-HRP) is added to the plate. The avidin binds to the 
biotinlabeled amplicons captured by the plate-bound oligonucleotide probes. 
The microwell plate is washed again to remove unbound Av-HRP and the 
substrate mixture containing hydrogen peroxide and tetramethylbenzidine 
(TMB) is added to each well. The reaction is stopped by the addition of dilute 
sulfuric acid and the absorbance of each well is read at 450 nm. To calculate 
the original concentration of the HIV-1 RNA, the Total HIV-1 optical density 
(OD) is divided through the total control RNA OD and multiplied by 40 x the 
number of control RNA copies that was used. The total HIV-I OD of the 
specimen is calculated by multiplying the OD of the HIV well with the lowest 
OD in the range of 0.2 to 2.0 OD units by the dilution factor associated with 
that well. Similarly, the Total control OD for the specimen is calculated by 
multiplying the OD of the control well with the lowest OD in the range of 0.3 
to 2.0 OD units by the dilution factor associated with that well. 
 
Procedure 
The standard specimen processing procedure that was used throughout the 
study allows the determination of the viral load from 400 to 750 000 RNA 
copies/ml. Whole blood was collected into standard blood collection tubes 
containing the anticoagulant ethylenediaminetetraacetate (EDTA, Sarstedt). 
Plasma centrifugation was performed at 1000x g for 20 minutes. 700µl of 
plasma / sample was then stored in screw-cap tubes at -80°C until viral load 
detection according to the instruction of the manufacturer. Viral Load 
determination was performed in part by trained laboratory personal according 
to the standard operating procedure accessible at http://aactg.s-
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3.com/pub/download/vir/AMPLICOR-HIV-1-MONITOR-TEST-Standard-
Method-Version-1.5.pdf. 
 
2.2.3 HLA typing 
HLA-A, -B, and -C class I alleles were typed by DNA sequencing on the 
automated sequencer ABI 3700 (Applied Biosystems, Applied Biosystems, 
Foster City, USA) essentially as described by Turner et al. (Turner et al., 
1998). DNA was extracted from 200 000 PBMC using the High Pure viral 
nucleic acid kit (Roche Diagnostics, Mannheim). Exons 2 and 3 (encoding the 
peptide binding groove) were amplified in a first round PCR as previously 
described (Turner et al., 1998). The initial exon 2-3 amplicon then served as a 
template for the nested and/or hemi-nested amplification of exon 2. Exon 3 was 
similarly amplified in a nested fashion. Both the first round and nested PCR 
primers are located in the introns flanking the amplified exon(s) (Turner et al., 
1998). The nested PCR primers are alternately tailed with an M13 universal 
DNA sequencing primer sequence. Bidirectional M13 cycle sequencing of 
exon 2 and of exon 3 was executed with BigDye V3.1. HLA DNA sequence 
typing analysis was completed with Assign SBT software (Conexio 
Genomics). DNA sequence ambiguities were resolved using the PEL-FREEZ 
SSP Uni tray kit (Invitrogen, USA). The HLA-typing of the specimen was 
facilitated by Steve Cate and Dr. William Hildebrand (University of Oklahoma 
Health Science Center). 
 
 
2.3 Separation, counting and cryo-preservation of peripheral blood 
mononuclear cells  
 
2.3.1 Buffers and solutions 
 
Freezing medium  
RPMI 1640 
Heat-inactivated FBS 20 % (v/v) 
DMSO        10% (v/v) 
Penicillin       100 U/ml 
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Streptomycin       100 µg/ml 
Gentomycin      0.25% (v/v) 
Fetal Bovine Serum was heat-inactivated for 30 minutes at 56°C. 
 
R10 medium  
RPMI 1640 
Heat-inactivated FBS        10 % (v/v) 
L-Glutamine               2mM 
Hepes buffer      10mM 
Penicillin            100U/ml 
Streptomycin              100µg/ml 
Fetal Bovine Serum was heat-inactivated for 30 minutes at 56°C. 
 
Trypane Blue solution (prepared with double destilled water) 
Trypane blue 0.36 % (w/v) 
NaCl 0.9 % (w/v) 
Trypane Blue solution was sterile filtrated with a syringe micro-filter 
 
2.3.2 Blood collection and plasma centrifugation  
From each subject 50 ml of blood was collected into CPTA tubes and delivered 
to the processing lab within 4 hours. The plasma was then separated from the 
cellular blood components by centrifugation at 400x g for 15 minutes at room 
temperature, dispensed into Plasma-Cryotubes and stored at -20°C for further 
serological assays or at -180°C for determination of the plasma viral load. The 
plasma was then replaced by adding the same amount of sterile PBS.  
 
2.3.3 Isolation of peripheral blood mononuclear cells (PBMC) 
Before adding the diluted cellular blood components, 15ml of Ficoll-Hypaque 
(Sigma, Deisenhofen) was added to the Leucosep tubes (Greiner, 
Frickenhausen, Germany) and centrifuged for 1 min. at 400x g. Leucosep tubes 
allow the separation of PBMC from diluted blood by Ficoll-Hypaque density 
gradient centrifugation. The diluted cellular blood components were then 
transferred into two 50ml Leucosep tubes. Centrifugation causes the PBMC to 
form a distinct layer at the PBS-Histopaque interface. Cells of higher density – 
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namely the granulocytes and erythrocytes – will be trapped in the lower part. 
Blood components of low density - the blood platelets - will remain in the 
supernatant. 
 
Procedure 
After adding the diluted blood into the Leucosep tubes, these were centrifuged 
at 1000 x g for 10 minutes at room temperature without using the centrifuge 
brake. After centrifugation the supernatant above the PBMC layer was 
carefully removed and the PBMC were transferred into a 50ml polypropylene 
tube (Becton Dickinson, Heidelberg). After transfer, the tubes were filled up to 
50ml with sterile PBS and centrifuged at 250g for 10 minutes at room 
temperature (the centrifuge break was adjusted to level 5). Subsequently, the 
supernatant was carefully discarded. This washing and centrifugation step was 
repeated once to get rid of any residual Ficoll-Hypaque and to dilute out the 
blood platelets. The pelleted PBMC were then re-suspended in a total of 10ml 
of pre-warmed (37°C) R10 medium, pooled into a single tube and kept at 37°C 
and 4.5% CO2 until PBMC were counted (see 2.3.4) and the amount of PBMC 
needed for the IFNγ-ELISPOT assay was removed. PBMC that were not 
directly used were cryo-preserved (see 2.3.5) 
 
2.3.4 Cell counting 
Accurate and consistent cell counting is a essential for the enumeration of 
antigen-specific PBMC with the IFNγ-ELISPOT assay (see 2.5). Cells were 
counted after trypane blue staining in a Neubauer cell counting chamber. 
Trypane blue is exclusively staining dead cells. The Neubauer cell counting 
chamber has 4 quadrants, with each quadrant having a grid of 16 squares. 10µl 
of PBMC sample was added into 90µl trypane blue, mixed well and added 
below the coverslide. For each sample all 4 quadrants were counted. The cell 
concentration is calculated from the mean number of cells/quadrant multiplied 
by 10 000 and the dilution factor.  
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 2.3.5 Cryo-preservation of cells 
PBMC for cryo-preservation were centrifuged at 250 x g for 10 minutes and 
the supernatant was discarded. Then the cell pellet was resolved gently by 
tapping. After any cell clumps were resolved, the tubes were transferred into a 
box with crushed ice. To adjust the cell concentration to 10 x 106 PBMC/ml the 
appropriate amount of 4°C cold freezing media was added. Without delay 
cryotubes were then transferred into special freezing containers (“Mr. 
Frosties”, Nalgene) and frozen down to -80°C inside the freezer. The freezing 
containers contain iso-propanol and approximately cool down with a rate of 
1°C/minute, which is considered optimal for the cell quality. After a maximum 
of 2 weeks, cryo-preserved cells were transferred into liquid nitrogen for long 
term storage. 
 
2.3.6 Thawing of frozen PBMC 
Vials of frozen PBMC were thawed inside a 37°C waterbath and cells 
immediately transferred into 10ml of prewarmed R10 medium containing 
2U/ml Benzonase (Novagen, Merck). Benzonase is a DNAse that is added to 
digest DNA released from dead cells that can contribute to cell clumping. The 
cell suspension was then centrifuged at 250 x g, the supernatant carefully 
discarded and the cell pellet resolved in 10ml of pre-warmed R10 medium. 
After another centrifugation step, cells were resolved in R10 medium and 
cultivated overnight at 37°C in 4.5% CO2 to exclude dying cells from the 
assay. 
 
2.4 Synthetic peptides and peptide matrices 
PBMC were screened for HIV-specific CD8 T cell responses by stimulation 
with overlapping peptide pools (OLP) representing Gag and Nef from isolates 
of subtypes A, C and D. OLPs consisted of 15mer or 18mer peptides 
overlapping by 11 amino acids covering the entire Gag, Nef or Env proteins 
Sequences are based on HIV-1 isolates 90CF402 (subtype A Gag, AAB38823), 
Du422 (subtype C Gag, CAD62240) 98UG57143 (subtype D Gag, AF484514), 
92UG037 (subtype A Nef, AAC97549), DU151 (subtype C Nef, AAL05314) 
and 94UG114 (subtype D Nef, AAC97574), Du179 (subtype C Env, 
CAD62243) and 98UG57143 (subtype D Env, AF484514).  
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Tab. 2.1: Peptides for restimulation 
 
Peptide set Isolate Length N° of peptides 
(matrix) 
Supplied by 
A-Gag 90CF402 15mer 123 (11 x 11) Anaspec. Inc, San 
Diego 
C-Gag Du422 15mer 123 (11 x 11) NMI, Tuebingen
D-Gag 98UG57143 15mer 123 (11 x 11) NMI, Tuebingen
A-Nef 92UG037 15mer 51 (7 x 7) NMI, Tuebingen
C-Nef Du422 15mer 49 (5 x 10) NMI, Tuebingen
D-Nef 94UG114 15mer 51 (7 x 7) NMI, Tuebingen
C-Env Du179 18mer 113 (11 x 11) NMI, Tuebingen
D-Env 98UG57143 15mer 179 (13 x 14) NMI, Tuebingen
CEF CMV, EBV, 
Influenca A 
8-12mer 23 (no matrix) Henry M. Jackson 
Foundation 
 
 
Procedure 
Peptides were synthesized using Fmoc chemistry and standard solid-phase 
techniques with free amino termini. All peptides were >80% pure as 
determined by HPLC, mass spectroscopy, amino acid analysis and N-terminal 
sequencing. The A Gag peptides were synthesized at the Henry M. Jackson 
Foundation and by Anaspec Inc (San Jose, USA). The rest of the peptides were 
synthesized by the Natural and Medical Sciences Institute (University of 
Tuebingen, Germany). Lyophilized peptides were resolved at a stock 
concentration of 10mg/ml in cell culture grade DMSO (Sigma, Deisenhofen).  
 
 To minimize the number of PBMCs used, initial screening for T-cell responses 
was performed using the OLPs in a matrix format. Subtype A, C, and D Gag 
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peptide sets were pooled in an 11 x 11 format, the A- and D-Nef peptide sets 
were pooled in a 7 x 7 format and the C-Nef peptide set was pooled in 10 x 5 
formats. To assure consistent quality of the assay, peptide matrices were 
aliquoted at a concentration of 50µg/ml/peptide into 96-well micro racks 
(Neolab, Heidelberg). Micro racks were sealed using plate sealers (Millipore, 
Schwalbach) and stored at -80°C until use. For each working day, one 96-well 
aliquot was thawn and peptides were diluted with R10 medium to a 
concentration of 4µg/ml/peptide. 
 
2.5 The IFNγ-ELISPOT assay 
The enzyme linked immuno spot (ELISPOT) assay for detecting individual 
cytokine-secreting cells is based on the use of highly specific antibodies 
against cytokines. The technique resembles a cytokine-specific Sandwich 
ELISA with the exeption that the bottom of each well is made of a 
polyvinylidene difluoride membrane. After the detection step, each IFNγ-
secreting cell results in one spot on the membrane, where the primary antibody 
had immobilized the secreted IFNγ. Its 96-well format, high sensitivity and 
consistency allows screening for antigen specific PBMC in a “high-
throughput” manner, which is crucial to map and enumerate HIV-specific 
cellular immune responses to individual peptides or peptide pools. In the 
HISIS-CTL study, the IFNγ-ELISPOT assay was combined with overlapping 
pooled peptide technology and has allowed efficient quantification and 
mapping of HIV-1-specific CD8+ T-cell responses by measuring interferon-
gamma (IFNγ) release (Addo et al., 2003; Betts et al., 2001). Whether specific 
CD8 or CD4 T cells are responsible for IFNγ secretion has been resolved in a 
second experiment using flow cytometry with the intracellular cytokine 
staining protocol (see 2.6).  
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Procedure  
Buffers and solutions  
PBS without Mg2+ und Ca2+ 
NaCl       8.0 g/l 
KCl       0.2 g/l 
Na2HPO4 x 12 H2O     2.9 g/l 
KH2PO4      0.2 g/l 
 
Wash buffer (made with PBS) 
FBS      1.0   % (v/v) 
Tween 20     0.001% (v/v) 
 
R10 medium  
RPMI 1640 
Heat-inactivated FBS        10 % (v/v) 
L-Glutamine               2mM 
Hepes buffer      10mM 
Penicillin            100U/ml 
Streptomycin              100µg/ml 
Fetal Bovine Serum was heat-inactivated for 30 minutes at 56°C. 
 
NoveRed substrate solution (included in the NoveRed substrate kit, Vector 
Laboratories) 
15ml of double distilled Water 
reagent 1   3 drops 
reagent 2   2 drops 
reagent 3   2 drops 
Hydrogen Peroxidase  2 drops  
 
The composition and the principle of the NovaRed substrate are company 
secretes. However, the principle of the colour reaction is likely to be based on 
the generation of free OH٠ radicals by the horseradish peroxidase and a color 
reaction that is dependent on the presence of free OH٠ radicals. The substrate 
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solution is light sensitive and was prepared 5 minutes before adding into the 
microplate wells inside 50ml Polypropylene tubes that were wrapped in tin foil. 
  
 
IFNγ-ELISPOT assays were performed as previously described with minor 
modifications (Mashishi and Gray, 2002). Polyvinylidene difluoride plates 
(Millipore Multiscreen-IP 96well, MAIPN0B10, Schwalbach) were coated 
with 50µl of anti-IFNγ monoclonal antibody 1-D1k (2µg/ml) (Mabtech, 
Stockholm, Sweden) overnight at 4°C and then blocked for a minimum of 2 
hours with R10 medium. Peptides were added directly to the wells at a final 
concentration of 2µg/ml along with 1 x 105 of fresh PBMC in 50µl of R10 
medium and were incubated at 37°C in 4.5% CO2. After 16 to 18 hours, plates 
were extensively washed 3 times with PBS and 3 times with wash buffer, 
followed by incubation with a biotinylated anti-IFNγ monoclonal antibody (2 
µg/ml) (clone 7-B6-1; Mabtech) at room temperature for 3 hours. After six 
more washes with wash buffer, 2µg/ml of streptavidin-horseradish peroxidase 
(Pharmingen, San Jose) was added to the wells, and the plates were incubated 
for another hour at room temperature. Spots were visualized by adding 100µl 
of NovaRed substrate (Vector, Burlingame) and 10-15minutes of incubation in 
the dark. The reaction was stopped by flushing the wells 2 times with water.  
 
Duplicate wells containing only PBMC and R10 medium were used as 
negative controls. Wells containing PBMC and 4µg/ml phytohemagglutinin 
(PHA) served as positive controls. Spots per well were counted with an 
Immunospot (Cellular Technology Ltd., Cleveland, Ohio) automated plate 
counter. Peptide responses were confirmed by using individual peptides in the 
ELISPOT assay with freshly isolated PBMC during FU14. 
 
2.5.1 Monitoring and evaluation of the assay consistency  
Differences in cell counting, pipetting or inconsistent sensitivity of the 
ELISPOT assay can hamper the quantitative analysis of T cell responses. 
Therefore assay variation and sensitivity was monitored throughout all follow 
ups using 4 batches of Quality control PBMC (QC-PBMC) that were donated 
by the same voluntary HIV-negative blood donor on 4 different time points. 
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The QC-PBMC responded to the CEF peptide pool containing 23 peptides 
from CMV, EBV, Influenza with a mean of 1400 spot forming cells (SFC)/106 
PBMC and a standard deviation of 247 SFC/106 PBMC. QC-PBMC were 
always recovered from frozen one day in advance of the IFNγ-ELISPOT assay 
(see 2.3.6). Two wells containing unstimulated PBMC and one containing 
CEF-stimulated PBMC were included on each Gag-peptide test plate. The 
maximum fluctuation of the assay - highest SFC: lowest SFC (fig 2.1) - was 
1.82 for FU12, 1.88 for FU13, 1.92 for FU14 and 1.7 for FU15.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. IFNγ-ELISPOT quality control throughout the HISIS-CTL 
study. Shown is the SFC/well of QC-PBMC after restimulation with the CEF 
peptide pool throughout follow up (=FU) 12 (left panel). The median is 
indicated in red. The median and average SFC/well for FUs 12, 14 and 15 are 
shown in the right panel. 
 
 
2.6 Intracellular cytokine staining (ICS) from whole blood 
The type cells and cytokine production was measured by flow cytometry with 
different fluorochrome-labled antibodies (see 2.2.1). Positive peptide-specific 
responses or responses to virus like particles (VLP-Pr55, generously provided 
by Prof. Ralf Wagner, University of Regensburg, Germany) were tested. To 
determine, whether the antigen-specific T cell responses were mediated by 
CD4 or CD8 T cells, the intracellular IFNγ expression was measured directly 
from whole blood.   
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Procedure 
250 µl of heparinized whole blood was added into polypropylene tubes and 
stimulated with either individual peptides (2µg/ml final), Staphylococcal 
enterotoxin B (SEB, 10µg/ml final) (Sigma, Deisenhofen) as a positive control, 
or left without stimulant as a negative control. All tubes contained 25µg/ml of 
co-stimulatory anti-CD28 and anti-CD49d monoclonal antibodies 
(Pharmingen, San Diego, CA), 25µg/ml of protein transport inhibitor brefeldin 
A (Sigma) and were incubated for 6 hours at 37°C in the presence of 4.5% 
CO2. Samples were then processed by lysing, fixation, permeabilization and 
staining according to the BD Bioscience standard whole blood assay analysis 
protocol (included in the package insert of the Becton Dickinson Fastimmune 
Kit for intracellular cytokine detection kit). Cells were stained with anti-IFNγ-
FITC (Pharmingen, clone 4S.B3), anti-CD4-PE (Pharmingen, clone RPA-T4), 
anti-CD8+-PerCp-Cy5.5 (BD Biosciences, clone SK1) and anti-CD3-APC 
(Pharmingen, clone UCHT1). Data acquisition was performed using a 
FACSCalibur flow cytometer (Becton Dickinson, Heidelberg), and data sets 
were analysed with FlowJo software (version 4) (TreeStar, Cupertino, CA). 
Responses of at least 3 times the negative control and at least 0.06% of CD8+ 
T cells were scored as positive. 
 
Tab 2.2: Antibodies used for ICS 
Antigen  Clone Conjugate pupose Company 
IFNγ 4S.B3 FITC staining Pharmingen 
CD4 RPA-T4 PE staining Pharmingen 
CD8 SK1 PerCp-Cy5.5 staining BD Bioscience 
CD3 UCHT1 APC staining Pharmingen 
CD28 555725 none co-
stimulation 
Pharmingen 
CD49d 555501 none co-
stimulation 
Pharmingen 
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2.7 Molecular characterization of the Virus by the Multi- 
Hybridization Assay 
The Multi-Hybridization Assay (MHA) is a real-time PCR based technique that 
was first introduced and validated against complete genome sequences for the 
ability to accurately distinguish subtypes and recombinant forms within 
amplified genomic regions (Hoelscher 2002). It was developed primarily for 
rapid discrimination of subtypes A, C and D and recombinant forms of HIV-1, 
but is also capable of detecting dual infections. The principle of the MHA is to 
amplify five short regions distributed along the HIV-1 genome in a separate 
first round PCR that does not discriminate between subtypes. Each amplicon is 
then distributed to three second-round PCRs, each with a different subtype-
specific probe labeled at the 5’ end with 6-carboxyfluorescein and a quencher 
at the 3’end (provided by Applied Biosystems, Darmstadt). Nested PCR 
primers and probes for the five genome regions, are termed gag , pol, vpu, env 
1 and env2. 
 
Procedure 
The template DNA was extracted from 200 000 PBMC using the High Pure 
viral nucleic acid kit (Roche Diagnostics, Mannheim). The first round PCR 
contained 250µM of each dNTP, 1.5mM MgCl2, 50mM KCl, 15mM Tris-HCl 
pH8.0, 1µM primers, with 3 Units AmpliTaq GOLD (Applied Biosystems, 
Darmstadt). The amplicons were 412-633 base pairs (bp) in length. The 
thermocycle routine was: 1 cycle of  95°C 10 minutes, then 35 cycles of 95°C 
15 seconds, 52°C 45 seconds, 72°C 90 seconds in an ABI9600 Thermocycler 
(Applied Biosystems, Darmstadt). The second round PCR reactions contained 
2µl of first round product, 250µM of each dNTP, 3.5mM MgCl2, 480nM 
primers, 220nM probe, 1.5 Units  AmpliTaq GOLD in 1x Taqman Universal 
Master Mix (Applied Biosystems, Darmstadt). PCR amplification was in a 96-
well spectrofluorometric ABI7700 sequence detection system (Applied 
Biosystems, Darmstadt) at 95°C for 15 second, 55°C 1 minute, and 60°C 1 
minute for 30-35 cycles. Fluorescence intensity was monitored during every 
cycle, and samples were considered positive, when the fluorescence intensity 
increased exponentially over at least 5 consecutive cycles. The MHA was in 
part performed by Martina Gerhardt at the Institute for Tropical Medicine and 
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Infectious Diseases in Munich and at the US Military HIV Research Program 
in Rockville. 
 
2.8 Prediction of CD8 T cell epitopes by HLA-specific binding motifs 
HLA binding motifs were predicted with the online HLA motif scanner tool at 
http://www.hiv.lanl.gov/content/immunology/motif_scan/motif_scan. This tool 
allows to find HLA anchor residue motifs within protein sequences for 
specified HLA alleles. Binding motifs are predicted predominantly on the basis 
of two HLA motif libraries (Marsh et al., 2000; Rammensee et al., 1999). HLA 
B4201 and B8101 binding motifs have been added to the database by Yusim et 
al. (Yusim et al., 2004). Epitopes can vary in length from 8 to 11 amino acids. It 
should be noted that binding motif prediction does not consider proteasome 
cleavage preferences within a given amino acid sequence. 
 
Table 2.3. Binding motifs of selected HLA B alleles considered in this 
work. Anchor residues displayed in round brackets are preferred but not 
dominant. Shown is the binding motif of the 8mer epitope. For prediction of 9-
11mer epitopes, amino acids are inserted in the position -1 before the C-
terminal position. This position is indicated as x. 
 
HLA allele 8 mer Motif  scource 
B0702 x-[P]-x-x-x-x-x-[L(F)] (Marsh et al., 2000) 
B0702 x-[P(V)]-x-x-x-x-x-[L] (Rammensee et al., 1999) 
B1503 x-[QK]-x-x-x-x-x-[YF] (Rammensee et al., 1999) 
B1510 x-[H]-x-x-x-x-x-[L(F)] (Rammensee et al., 1999) 
B4201 x-[P]-x-x-x-x-x-[L] (Yusim K et al., 2004) 
B57 x-[ATS]-x-x-x-x-x-[FW] (Marsh et al., 2000; 
Rammensee et al., 1999) 
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Table 2.3 (continuation) 
 
 
2.9 Statistical analysis 
Statistical analysis of the data was performed in part with the "Prism V3.00 
Software" (Graphpad). The statistical tests used are indicated in the results 
chapter. In general, non-parametric tests were used to describe and analyze the 
data, since cellular immune response data generally does not follow a normal 
distribution.  In chapter 3.2, responses of the population to an individual 
epitope (single peptide) were calculated as median values of all subjects 
responding to a particular peptide in the original screening assay. To determine 
if there was a statistical difference in response to peptide variants among the 
three peptide sets, the responses were analyzed using the Friedman Test - a 
non-parametric, repeated measures ranking test for comparing three or more 
treatment groups. When the null hypothesis was rejected (p<0.05), a post hoc 
test (Dunn's multiple comparison test) was used to test for response differences 
between the pairs of groups. 
 
HLA allele 8 mer Motif  scource 
B5801 x-[ATS]-x-x-x-x-x-[WF] (Marsh et al., 2000) 
B5801 x-[AST(G)]-x-x-x-x-x-[FW(Y)] (Rammensee et al., 1999) 
B5802 x-[ST]-x-x-x-[R]-x-[F] (Marsh et al., 2000; 
Rammensee et al., 1999) 
B8101 x-[P]-x-x-x-x-x-[L] (Yusim K et al., 2004) 
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3. Results 
 
3.1 Recognition of multiple epitopes within two regions of Gag is 
associated with a low viral load  
A recent report by Kiepiela et al 2004 demonstrated a dominant influence of 
HLA class I B alleles on the HIV disease progression in chronically HIV-
infected individuals. Particular B alleles, namely B5801, B57, B4201 and 
B8101 were significantly associated with a lower than median viral load, 
whereas others, such as B5802 and B4501 were associated with a higher than 
median viral load. It was further demonstrated that HLA B alleles contribute 
most to the HIV-specific CD8 T cell response (67% of CD8 T cell responses 
restricted by B alleles) if compared with HLA A or HLA C alleles ((Kiepiela et 
al., 2004), indicating that there may be a mechanistic link between the HIV-
specific CD8 T cell response restricted by a particular HLA B allele and the 
corresponding viral load.  
 
Therefore in order to study the mechanism underlying the beneficial effect of 
protective HLA class I alleles, the HLA alleles of 53 study subjects from the 
HISIS-CTL cohort (described in chapter 2.2) were typed and the plasma viral 
load and CD4 counts determined. At the same time the HIV-specific CD8 T 
cell response of the study subjects was examined for responses to Gag, Nef and 
Env with an IFNγ-ELISPOT assay and intracellular cytokine staining for IFNγ. 
 
3.1.1 HLA class I alleles B5801, B8101 and B0702 are associated with a 
low viral load during chronic HIV-1 infection 
As stated above, particular HLA class I B alleles are associated with a low viral 
load during chronic infection. Therefore the HLA allele expression and the 
plasma viral load were determined for study subjects within the HISIS-CTL 
cohort as described in the materials and methods chapter. The most common 
HLA B alleles were B4201 (n=12) followed by B5301 (n=10), B5802 (n=9), 
B8101 (n=9), B0702 (n=8) and B1510 (n=8). The “protective” B alleles B5801 
and B5703 were less common (n=4) (Fig. 1A).  
Median plasma viral load for the HISIS-CTL cohort was 198 500 RNA 
copies/ml, a value much higher than seen in most other studies (Kiepiela et al., 
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2004 ; Masemola et al., 2004; Mellors et al., 1996; Novitsky et al., 2003),. 
B5801 expressing subjects had the lowest median viral load (17 250 RNA 
copies/ml), followed by subjects expressing B8101 (19 360 RNA copies/ml), 
B0702 (45 350 RNA copies/ml), B5703 (67 250 RNA copies/ml) and B4403 
(85 800 RNA copies/ml). In contrast B5802, B4501, B1510 and B4201 had a 
median plasma viral load of close to or above 200 000 RNA copies/ml. These 
results indicate that similar associations between particular HLA-B alleles and 
plasma viral load are seen in the HISIS-CTL cohort and the cohort of the 
Kiepiela study, except for allele B4201 (Kiepiela et al., 2004).  
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Fig. 3.1. HLA allele frequencies and plasma viral load among HISIS-CTL 
subjects. (A) Frequencies of HLA class I alleles in the HISIS-study cohort. 
Alleles that were associated with low median plasma viral load of below 50 000 
are indicated in red (n=53). (B) HLA class I expression and plasma viral load 
in chronically infected study subjects (n=55). The red line indicates the median 
viral load of the HISIS-CTL cohort (198 000 RNA copies / ml). 
3.1.2 Protective HLA B alleles are associated with a broad Gag-specific 
CD8 T cell response 
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Next it was examined whether subjects expressing HLA alleles that were 
associated with a median plasma viral load of below 50.000 RNA copies/ml 
(B5801, B8101 and B0702 - for simplicity referred to as “protective” HLA 
alleles) differed in the number of Gag, Nef or Env epitopes recognized. 
Therefore the peptide recognition by PBMCs was tested with the IFNγ-
ELISPOT assay using overlapping peptide matrices of Gag, Nef and Env from 
HIV subtypes A, C and D. Responses to individual peptides were confirmed in 
a second step by single peptide retesting. To determine the phenotype of the 
responding cells, a total of 82 individual peptide responses from 20 study 
subjects were subjected to cytokine flow cytometric analysis for IFNγ 
production and confirmed the same peptide responses as detected with the 
ELISPOT assay. Eighty-nine percent of responses were from CD8+ T-cells 
(data not shown).  
 
For each tested HIV protein, the frequency of responding CD8 T cells and the 
number of CD8 T cell epitopes recognized was analyzed and compared for 
study subjects expressing “protective” HLA alleles and those that were 
associated with a viral load of above 50 000 RNA copies/ml (all other B 
alleles) (Fig.3.2). There was a significant difference between subjects 
expressing “protective” HLA B alleles and non-expressing subjects in the 
number of epitopes recognized (single peptide or the first of a pair of 
overlapping peptides) within Gag with a median number of 4 and 2 recognized 
epitopes respectively (p-value = 0.0035, Mann-Whitney Test). The frequency 
of total Gag-specific CD8 T cells was not significantly different between both 
groups, although the median Spot-forming cells (SFC)/106 PBMC was doubled 
for subjects expressing a “protective” HLA allele with 2840 SFC/106 PBMC. 
For Nef and Env specific CD8 T cell responses, there were no differences 
between both groups in the number of epitopes recognized (data not shown for 
Env) or in the frequency of specific CD8 T cells (data not shown). Within Nef, 
the number of epitopes recognized was a median of 2 and the median 
frequency was 1600 SFC/106 PBMC for either group. However, three of four 
HLA B5801 expressing subjects had a very broad Nef response with 11 or 12 
Nef epitopes recognized. The HLA alleles B57 and B44, both of which were 
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associated with a median viral load below 100 000 RNA copies/ml, were not 
associated with a broad Gag or Nef epitope recognition (data not shown).  
Taken together these results suggest that the HIV-specific CD8 T cell response 
of subjects expressing “protective” HLA class I alleles B5801, B8101 and 
B0702 (n=18) is characterized by a broad number of epitopes recognized 
within Gag.  
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Figure 3.2. Expression of “protective” HLA Class I alleles correlates with 
a broad Gag-specific CD8 T cells response. Shown is the number of 
recognized epitopes for (A) Gag and (B) Nef from study subjects who express 
”protective” HLA B alleles (n=16, red dots) and from study subjects expressing 
other HLA B alleles (n=37, black dots). “Protective” HLA alleles were defined 
as those associated with a median viral load below 50 000 RNA copies/ml in 
the HISIS CTL-cohort (alleles B5801, B8101 and B0702). Recognition of two 
consecutive peptides was counted as 1 epitope response. Statistical analysis 
was performed using the Mann Whitney test. 
 
 
3.1.3 Linear relationship between the number of Gag epitopes 
recognized and the plasma viral load 
As stated above a significant difference was found for the HIV-specific CD8 T 
cell response for subjects expressing “protective” HLA alleles B5801, B8101 
and B0702 was the number of recognized Gag epitopes. Neither was the 
frequency of Gag-specific CD8 T cells significantly elevated, nor appeared the 
Nef or the Env specific response to be any different between subjects 
expressing “protective” HLA B alleles and subjects who do not express a 
“protective” HLA allele. Could a broad number of recognized Gag epitopes be 
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beneficial to the HIV-infected subject and serve as a predictive marker for 
disease progression in general? To clarify this question, we compared the 
breadth of epitope recognition and the frequency of protein-specific CD8 T 
cells with the plasma viral load and the CD4 cell count. As shown in figure 3.3 
there was a negative linear relationship between the number of recognized 
epitopes within Gag and the plasma viral load [p-value = 0.0016 (Spearman-
Rank Test), R-linear = -0.36] and a positive linear relationship between the 
number of recognized epitopes within Gag and the CD4 cell count [(p-value = 
0.013 (Spearman-Rank Test), R-linear = 0.33]. The frequency of Gag-specific 
CD8 T cells was not correlating with a low plasma viral load. Neither did the 
Nef- or Env-specific CD8 T cell response correlate with a low plasma viral 
load nor with the CD4 cell counts (data not shown). However, up to 5 
recognized epitopes within Nef, there was a positive linear relationship 
between the number of recognized epitopes and the plasma viral load and a 
negative linear relationship with the CD4 cell counts. This relationship is 
strong up to 5 Nef epitopes recognized (93% of subjects fall into this group) 
and is reversed with recognition of more than 6 Nef epitopes (4 subjects only, 3 
of the 4 express B5801).  
 
These results indicate that the breadth of the Gag-specific CD8 T cell response 
appears to be of particular importance for the control of viral replication during 
chronic HIV-1 infection. In contrast Nef and Env-specific responses did not 
contribute to efficient control of viral replication, suggesting that CD8 T cells 
of different specificities may vary in their respective antiviral efficiency. 
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Figure 3.3. Linear relationship between Viral load and CD4 counts with the number of recognized epitopes within 
Gag, but not within Nef or Env. Shown are (A) the linear regression analysis of the viral load and (B) the CD4 count versus 
the number of epitopes recognized per subject for Gag (left panels), Nef (middle panels) and Env (right panels). Recognition
of two consecutive peptides was counted as 1 epitope response. Statistical analysis was performed using the Spearman-Rank
Test.
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3.1.4 Eighty-nine percent of subjects with efficient control of viral 
replication recognize multiple epitopes within 2 regions of Gag 
The finding that neither Nef- nor Env-specific CD8 T cell responses were 
associated with a lower viral load raised the question, whether there are 
differences in the antiviral efficiency between different Gag-specific peptide 
responses. To approach this question, Gag peptides recognized by subjects with 
a viral load below 50 000 RNA copies/ml (n=18; low viral load (LVL)-group) 
were compared with those recognized by subjects with a viral load above       
50 000 RNA copies/ml (n=36; high viral load (HVL)-group) (Fig.4). There 
were striking differences in the CD8 T cell specificities between these two 
groups. The average LVL-subject not only recognized more peptides within the 
whole Gag protein (factor 1.41), but also differed in the preferential Gag 
regions targeted compared to the HVL-group. LVL-subjects recognized 
peptides within the N-terminal region of Gag (GagR1, aa001-aa075, peptides 
1-16) almost twice as often (factor 1.80) compared to the HVL-group. Peptides 
within the C-terminal Gag region (GagR3, aa248-aa500, peptides 62-120) were 
recognized twice as often (factor 2.02), whereas peptides within the middle 
region of Gag (GagR2, aa076-aa247, peptides 17-61) were recognized equally 
among both groups (factor 0.93). These findings suggest that Gag regions 1 
and 3 are rich in epitopes whose recognition is important for efficient viral 
control. 
 
For the whole Gag protein, recognition of 5 or more epitopes is required to 
significantly reduce the median viral load (p-value=0.047, Mann-Whitney Test, 
data not shown) and significantly increase the median CD4 cell count (p-
value=0.024). However, only a limited number of 11 subjects recognized that 
many epitopes within the Gag protein, 7 of which had a viral load below        
50 000 RNA copies/ml. By excluding the central region of Gag R2, recognition 
of 2 or more epitopes within GagR1R3 correlated strongly with a low viral 
load (p-value=0.015) and a higher CD4 cell count (p-value= 0.016) (fig.3.5). 
16 of 29 subjects, who recognized 2 or more epitopes within GagR1R3 had a 
viral load below 50 000 RNA copies/ml, whereas only 3 of 26 subjects who 
recognized only 0 or 1 epitope within GagR1R3 were falling into this category  
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Figure 3.4. Comparison of Gag-specific CD8 T cell specificities of subjects with a plasma viral load below (n=19) 
or above (n=36)  50 000 RNA copies/ml. Shown is the frequency of responses after smooth local average with 
Gaussian kernel weights and a standard deviation (bandwidth) of 1 peptide.
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– two of these were expressing B5703 (indicated as red boxes in fig.3.5). 
Hence, 16 of 19 (86%) subjects with a viremia below 50 000 RNA copies/ml 
targeted at least 2 epitopes within GagR1R3. The strong correlation of 
protective HLA-B-alleles B5801, B8101 and B0702 expression with a broad 
epitope recognition within GagR1R3 (p-value=0.0022, data not shown), 
suggests that the low viremia may indeed be the result of the antiviral 
efficiency of a HIV-specific CD8 T cell response that is targeting multiple 
epitopes within GagR1R3.  
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Figure 3.5. CD8 T cell recognition of multiple epitopes within Gag regions 
aa001-aa075 and aa248-aa500 (Gag R1R3) is associated with efficient viral 
control. Shown is the viral load (A) and the CD4 cell count (B) of subjects 
with a broad (n=29) or narrow (n=26) CD8 T cell response against GagR1R3. 
Cut-off value was 2 epitopes recognized. The respective median and the 
interquartile range are indicated. HLA B5703 expressing subjects are indicated 
as red squares in the left panel. Recognition of 2 consecutive peptides was 
counted as 1 epitope response. Statistical analysis was performed using the 
Mann Whitney test (two tailed). 
 
 
3.1.5  Recognition of multiple epitopes within Gag R1R3 is not associated 
with the Gag-specific CD4 T cell response 
The antiviral efficiency of a CD8 T cell response could theoretically be 
influenced by the frequency in HIV-specific CD4 T cells. In order to analyse 
this, the whole blood of 38 study subjects was tested for IFNγ and IL-2 
expressing CD4 T cells after stimulation with subtype B virus like particles 
VLP-Pr55 during FU16. As shown in figure 3.6 there was no association of the 
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VLP-Pr55-specific CD4 T cell response with the GagR1R3 specific CD8 T cell 
response. In general only low frequencies of Gag-specific CD4 T cells were 
found that were predominantly secreting IFNγ and very little IL-2. 
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Figure 3.6 Frequency of Gag-specific CD4 T cells in subjects who do 
recognize (n=20) or do not recognize (n=18) multiple epitopes within 
GagR1R3. Shown is the frequency of IFNγ (left panel) or IL-2 (right panel) 
expressing Gag-specific CD4 T cells detected after restimulation with VLP-
Pr55. The background was subtracted. The median is indicated.  
 
 
3.1.6 Recognition of multiple epitopes within Gag R1R3 is associated 
with the maintenance of a low viral load 
 HIV infection is characterized by a typical course of the plasma viremia. 
During the acute phase, plasma viremia rises to peak levels within the first 3 
months and, with the initiation of the HIV-specific immune response, is 
subsequently dropping to the “viral load set point” (introduction fig.1.6). The 
viral load set point also allows estimating the time to AIDS (Mellors et al., 
1996). After primary infection, usually stays on a steady-state level with 
relatively little variation until it starts to rise again during the final AIDS phase 
of HIV infection. This typical course of viremia indicates that the outcome of 
an HIV-infection is largely determined during the acute phase of HIV-
infection. Therefore it was interesting to see whether the recognition of 
multiple epitopes within GagR1R3 would be associated with the establishment 
of the viral set point viremia and subsequent steady-state viral load levels.  
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To address that question, the course of the plasma viremia was studied in 19 
subjects that seroconverted during the HISIS study. In the group recognizing 2 
or more epitopes (n=12) the course of plasma viremia is typical for HIV 
infection (fig. 3.7 top panel). During the acute phase viral load rises to a 
median peak level of 286 000 RNA copies/ml and drops down subsequently to 
a steady state level of 10-20 000 RNA copies/ml for the next 24 months. Only 
2 of 12 subjects have a viral load of above 50 000 RNA copies/ml at 24 months 
past seroconversion. In stark contrast the course of plasma viremia of subjects 
recognizing less than two epitopes within GagR1R3 (n=7; HLA B57 
expressing subjects excluded) is strikingly different. Plasma viral load rises to 
peak levels with a median of 403 000 RNA copies/ml during acute infection 
and subsequently stays at a steady-state viremia of 150 000 to 350 000 RNA 
copies/ml over the next 24 months. At 24 months after seroconversion none of 
this group has a viral load below 50 000 RNA copies/ml and only one just 
below 100 000 RNA copies/ml. Hence viral replication is never brought under 
efficient control in any of these subjects. These results indicate that after the 
acute phase peak viremia, the recognition of multiple epitopes within the 
GagR1R3 may strongly contribute to a low viral set point and the maintenance 
of a low steady-state viremia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
months since seroconversion
Lo
g 1
0
R
N
A 
co
pi
es
/ m
l
-1 SC 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48
3
6
5
4
-1 SC 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48
3
6
5
4
Lo
g 1
0
R
N
A 
co
pi
es
/ m
l
                                                                                               Results 
 55
Figure 3.7. Dynamics of the plasma viral load after seroconversion (SC) 
Shown is the viral load  since seroconversion of study subjects who (A) 
recognized two or more epitopes (n=7) or (B) 0 or 1 epitope (n=12) within the 
Gag regions aa001-aa132 and aa297-aa500. The median viral load is indicated 
in red. Gag peptide responses were determined during FU14 with the IFNγ-
ELISPOT assay. Three HLA-B5703 expressing subjects were excluded from 
analysis. Recognition of 2 consecutive peptides was counted as 1 epitope 
response. 
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3.2 A minimal set of 15 peptides can cover the CD8 T cell response 
against HIV-1 Gag and Nef of subtypes A, C and D in a population 
affected by a mixed epidemic 
 
The genetic variability of HIV-1 is a major obstacle for both vaccine design 
and immunological screening methods (Brander 2003; Walker 2001, Gaschen 
2003).  Geographically defined epidemics can be characterized by the 
dominance of distinct genetic subtypes of HIV-1. At least 9 subtypes and 16 
circulating recombinant forms (CRFs) are currently described 
(http://www.hiv.lanl.gov/content/hiv-db/CRFs/CRFs.html). To complicate 
matters, intra-subtype variability can account for amino acid sequence 
differences of up to 25%, depending on the protein considered. Even within a 
single HIV-1 infected individual, the HIV mutant spectrum or so-called 
quasispecies that developes over the years of infection can reach a divergence 
of 10% (Meyerhans et al., 1989, Plikat et al., 1997). Yet, how this genetic 
diversity translates into an immunologically relevant diversity is not 
completely established.  
 
In this chapter the influence of subtype diversity on the CD8 T cell recognition 
was examined. Subtypes of the infecting HIV-1 strains were analysed, T cell 
responses were mapped to individual peptides within Gag and Nef. 
Furthermore the relative cross-recognition of subtype A-, C- and D-specific 
peptide variants was examined for the most frequently recognized antigenic 
peptides. The results were used for the design of a peptide pool of the most 
frequently recognized HIV-1 peptides within Gag and Nef, which was tested 
for recognition with seropositive subjects outside the HISIS cohort. 
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3.2.1 Subtype C and AC/ACD recombinant viruses make up the 
majority of HIV-1 infections in the Mbeya region of Tanzania 
To determine the subtype of the infecting strain of HIV-1 in each seropositive a 
Multi Hybridization Assay (MHAacd) (Hoelscher et al., 2002) was performed 
on up to 14 follow-ups per participant. This assay probes for the genetic 
subtype in multiple regions of the HIV-1 genome, one of which is the gag gene 
relevant to this study. As shown in figure 3.7, HIV-1 infections in the HISIS-
CTL cohort include subtypes A, C and D, with predominance of subtype C and 
subtype C-containing unique recombinant forms (URFs). 19 subjects were 
infected with HIV-1 subtype C, 3 with subtype A, and 29 subjects were 
infected with recombinant forms of HIV-1, mostly AC and ACD. The gag 
region subtype distribution closely matched that observed over the entire HIV-
1 genome for the 56 analysed subjects.  
 
Additionally, 27 gag gene sequences from discarded HIV positive blood 
donations from the blood bank of the Mbeya Referral Hospital confirmed that 
the subtype A, C and D Gag peptide sets used in this study were consistent 
with and generally representative of HIV-1 strains circulating in Mbeya region 
(fig 3.8). 
 
 
 
Figure 3.7. HIV-1 subtype distribution within the HISIS-CTL cohort. 
Shown are the results of the Multi Hybridization Assay analysis for the whole 
genome (A) and the gag gene (B). The frequencies of the detected pure and 
recombinant HIV-1 strains are given in percent. (NC- not conclusive) 
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Figure 3.8. Phylogenetic relationship between subtype A, C and D Gag peptide sets and HIV Gag protein sequences
from the Mbeya region in Tanzania.
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3.2.2 HIV-1 Gag and Nef are frequent targets of a broad CD8 T cell 
response in HIV-1 infected Tanzanians 
A peptide matrix-based IFNγ-ELISPOT assay was used to screen for HIV-1 
Gag- and Nef-specific T-cell responses in the 56 HISIS-CTL cohort subjects. 
To maximize detection in this mixed-subtype epidemic, three peptide sets, 
representing subtypes A, C and D Gag were selected. Confirmation of positive 
peptide responses was carried out 3 months later during the next follow up 
using only the peptide inducing the highest response from the A, C or D 
peptide sets. Ninety-six percent (n=54) of the HISIS-CTL cohort responded to 
at least one Gag peptide, while 93% responded to at least one nef peptide, and 
all study subjects responded to PHA. A total of 82 individual HIV-specific 
responses were subjected to cytokine flow cytometric analysis for IFNγ 
production to determine the phenotype of the responding cells and confirmed 
the same responses as detected with the ELISPOT assay. Eighty-nine percent 
of responses were from CD8 T cells (data not shown).  
 
To compare the responses among the three peptide sets, the frequency of 
responses against each linear pool of 11 consecutive Gag peptides, derived 
from the screening assay, was determined for the cohort. Subtype C peptides 
were recognized more frequently compared to subtype A or D peptides across 
the entire Gag protein (fig. 3.9 A). This is expected for this epidemic as 
subtype C and C-containing recombinants predominate. Further analysis of all 
individual Gag responses underscores the superiority of the subtype C peptides 
for detecting CD8+ T-cell responses in this cohort (fig 3.9 B). Of the 180 Gag-
specific responses detected, 149 (83%) were detected with the C-peptides, 103 
(57%) with the D-peptides and 91 (51%) with the A-peptides. The Venn 
diagram of relative cross-recognition of individual linear peptide pools (fig. 3.9 
B) also shows that 98 (54%) of the responses detected by the C-peptides were 
also detected by the subtype A- and D-peptides, but 51 (28%) were detected 
only with the subtype C-peptides. Subtype A- and D peptide sets detected 31 
responses not detected by the C-peptides. Of note, 56 (31%) of the responses 
were detected with all three peptide sets and may represent broadly 
crossreactive CD8+ T-cell epitopes.  
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Figure 3.9. Comparison of recognition among the HIV-1 Gag peptide sets 
within the HISIS-CTL cohort. Fifty-six HIV-1 positive study subjects were 
screened with a peptide matrix-based IFNγ-ELISPOT assay for recognition of 
subtype A, C, and D Gag-specific peptide sets. (A) Peptide pools containing 11 
successive overlapping peptides are represented on the x axis and the 
corresponding frequency of responding study subjects (n=56) with a response 
to the subtype A, C or D peptide pool is represented on the y axis. (B) Subtype-
specific distribution of the total number of detected T-cell responses against all 
Gag peptide pools. 
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A composite frequency distribution of the response to any individual peptide 
from either Gag or Nef was constructed (fig. 3.10, panels A and B). The p24 
protein of Gag was targeted with the highest frequency of subjects (91%), 
followed by p17 (56%) and the p15 proteins (15%). The breadth of Gag 
recognition for each individual was a median of 3 epitopes (a single peptide or 
pair of adjacent overlapping peptides), with a range of 0-10 epitopes (fig. 3.10, 
panel C). The magnitude of single peptide responses ranged from 70-5850 
SFC/106 PBMC. As reported by others (Addo et al., 2003; Frahm et al., 2004; 
Masemola et al., 2004; Novitsky et al., 2002), regions with hot spots of 
immune recognition within the Gag protein were detected: aa10-aa47 
(recognized by 45% of subjects); aa143-aa197 (64%) and aa291-aa321 (46%). 
The Nef protein was targeted by 93% of study subjects (n=52). As shown in 
figure 3.10 (panel B) the majority of responses against Nef were detected in the 
central region of the protein, which is in agreement with previous findings 
(Addo et al., 2003; Frahm et al., 2004; Masemola et al., 2004; Novitsky et al., 
2002). Hot spots of immune recognition were detected at the highly conserved 
regions aa78-aa108 (targeted by 78% of subjects) and aa125-aa159 (71%). The 
breadth of Nef-specific responses was a median of 2 epitopes per subject with a 
range of 0-12 (fig. 3.10, panel D). The magnitude of single peptide responses 
ranged from 70-3440 SFC/106 PBMC. Thus, both gag and nef gene products 
are frequent and consistent targets of the CD8+ T-cell responses in the HISIS-
CTL cohort. 
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Figure 3.10. Frequency distribution and breadth of the Gag- and Nef-specific T-cell responses detected in the HISIS-CTL 
cohort. Individual peptide responses were confirmed for the 56 HIV-1 positive study subjects in an IFNγ-ELISPOT assay and are 
shown for Gag (A) and Nef (B). The frequency of responders is given in percent. Peptides that were further analysed for cross-
recognition are highlighted with arrows. Peptide numbers are represented on the x axis. The breadth of the Gag (C) and Nef (D) 
response per study subject is also shown. Responses to 2 consecutive peptides were counted as 1 epitope response.
Nef
Gag
Table 1. HLA-associations of the most commonly recognized peptides from the HISIS-CTL cohort.
Analysed for
Peptide # Subtype Sequence HLA-Association Comments FRP-pool Crossreactivity
Gag5 D EKIRLRPGGKKKYRL B4201/B8101 (4/5)**    Described* n y
Gag7 C GKKHYMLKHIVWASR A2301 (8/11)   Not described y y
Gag20 C SLYNTVATLYCVHEK A02/A6802 (7/8)    Described* y y
Gag35 C GQMVHQAISPRTLNA B5802 (4/5)   Not described n y
Gag36 D HQAISPRTLNAWVKV B57/B58 (8/8)    Described* y y
Gag45 C TPQDLNTMLNTVGGH  B7/B42/B8101(20/22)    Described* y y
Gag50  C MLKDTINEEAAEWDR B5301 (3/6)    Described* y y
or A6802 (4/6)   Not described
Gag53 C WDRLHPVHAGPIAPG A6802 (4/5)   Not described y y
   Gag72/73 C GPKEPFRDYVDRFFK B8101 (6/7)    Not described y (Gag73) y
Gag74/73 C YVDRFFKTLRAEQAT B1503/B1510 (9/12)    Described* y (Gag73) y
Gag76 C LRAEQATQEVKNWMT B5301/B5801 (5/6)    Described* y y
 Gag83   C TILRALGPGATLEEM  B1503/B1510 (4/8)   Not described y y
TILRALGPGATLEEM  and B8101(4/8)   Not described y
Gag88 D ACQGVGGPSHKARVL B7/B42/B8101 (9/9)    Described* y y
Nef2 A WSKSSIVGWPAVRER {B7/B42/B8101 (4 of 6)}   Not described y y
Nef18 C PVRPQVPLRPMTYKA B7/B42/B8101 (18/24)    Described* y sequence identical
Nef21 C YKAAFDLSFFLKEKG {B1503/10/16 (7/12)}   Not described y y
Nef29 C WVYHTQGYFPDWQNY B5703 (4/9)    Described* y y
Nef33/34 C VRYPLTFGWCFKLVP A2301(10/21)    Described* y (Nef33) sequence identical
 or A6802(8/21)   Not described
B5301 (8 of 21)    Described*
 * described in HIV Immunology and HIV/SIV Vaccine Databases 2005: http://www.hiv.lanl.gov/immunology; 
** X of Y responding subjects express indicated HLA class I allele
FRP-pool = included in pool of frequently recognized peptides
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3.2.3 Frequently recognized peptides are associated with common HLA 
alleles in the cohort 
HLA-typing of the A, B and C alleles from the 56 subjects in the cohort was 
performed as described in Methods and Materials. Allele frequencies for each 
detected allele are shown in figure 3.1. The 13 most frequently recognized Gag 
peptides and the 5 most frequently recognized Nef peptides (denoted by arrows 
in figure 3.10) were analyzed in greater detail. In addition, responses to each 
epitope (single peptide or a pair of 2 consecutive peptides) correlated with 
possession of a single common HLA-allele or HLA super-family present in the 
cohort (table 3.1). Many of the responses could be attributed to minimal 
epitopes and HLA associations. Seven of the peptides were displaying 14 
associations with HLA alleles and are described in this work for the first time. 
12 peptides contained previously described epitopes with known HLA-allele 
restrictions. Strikingly, all of the subjects in the cohort recognized one or more 
of these 18 peptides. 
 
3.2.4 Discordance in the recognition of subtype derived peptide sets is a 
result of both sequence variation and frame-of-epitope positioning within 
a 15mer peptide 
To determine the extent of cross-recognition in commonly recognized 
antigenic regions, the most frequently recognized peptides within Gag and Nef 
were analyzed for disparity of recognition among the different peptide sets 
used for screening. The median response of confirmed responders to the A, C 
and D variants of 16 peptides was analyzed. Figure 3.11 shows recognition of 
subtype A, C and D peptide variants for study subjects responding to peptides 
Gag5, Gag7, Gag20, Gag45, Gag73/74 and Gag83 and is exemplary for the 
analysis of all 16 antigenic regions shown in Figure 3.12. Additionally in figure 
3.11 the gag MHA result for each study subject is shown below the sample ID. 
Two peptides (Nef18 and Nef34) with identical epitope sequences for all 
subtype variants were excluded from figure 5 as there was no difference in the 
magnitude of recognition among the three versions of these peptides. A 
statistical  difference  in  the median  response to the three peptide variants was  
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Figure 3.11.  Recognition of subtype A,  C and D derived peptide variants for
antigenic regions Gag7, Gag20, Gag45, Gag5, Gag73/74 and Gag83. Shown is
the SFC/106 PBMC  of confirmed responding subjects after peptide stimulation ex 
vivo. The sample ID and the gag MHA results of each subject is given on the x axis.
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observed in 11 of the 16 responses (Friedman test, p<0.05). The pair, or pairs, 
of peptides that elicited different responses were then identified using Dunn’s 
multiple comparison test. In those cases that didn’t reach statistical 
significance, a trend towards a difference in the median response was evident 
(fig. 3.12 E, L and N).  
 
During this study the observed magnitude of T cell responses measured against 
multiple overlapping peptides sets was affected not only by sequence 
differences of the peptides, but was also due to insertion/deletion 
polymorphisms affecting the relative positioning of the epitopes. Disparate 
recognition of 10 of 16 antigenic regions could be directly attributed to 
sequence variation within the compared peptides (reduction in median 
magnitude of responders), while frame-of-epitope shifting (the position of a 
minimal 9-mer or 10-mer epitope within a 15-mer peptide) contributed to 
diminished recognition of 4/16 epitopic regions (fig.3.12 F, G, J and K). As 
demonstrated in figure 3.11 differences in the magnitude of response to the 
three peptides could, in the p17 region, be directly attributed to sequence 
variation between the peptide sets. In 9 cases it was impossible to determine 
whether discordant peptide recognition was the result of point substitution or a 
result of the epitope position within the 15-mer peptide. In spite of sequence 
identity of the minimal B42/B81-restricted epitope TL9 (TPQDLNTML; fig. 
3.11C and fig. 3.12 F), the median response of 11 subjects to the subtype C 
peptide (1030 SFC/106 PBMC) was decreased over 5 fold when using the 
subtype D peptide (180 SFC/106 PBMC). Here, only the position of the 
minimal epitope within each 15-mer differs between the two peptides and 
affects the detected magnitude of the T-cell response. The T→M substitution in 
the subtype A peptide (containing the minimal epitope in the same position as 
the subtype D peptide) resulted in a further two-fold reduction in median 
recognition (90 SFC/106 PBMC) and was recognized poorly by Gag45 
responders (fig. 3.11). Of note, the preceding peptide in the subtype C pool 
(Gag44) showed only a slightly decreased frequency of recognition compared 
with peptide Gag45 even though the minimal epitope is in a different frame in 
these two peptides. Similar observations were made for the antigenic regions 
Gag74  and Gag72  (fig. 3.12 J and K).   Nonetheless, for Gag p17 the relative 
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Figure 3.12. Comparison of the median T-cell responses to subtype-
derived peptide variants of the 16 most frequently recognized antigenic 
regions in gag (n=13) and nef (n=3). Shown is the median SFC/106 PBMC of 
study subjects after peptide stimulation ex vivo. Peptide numbers and 
sequences are annotated. The response to 2 dominant regions in Nef (Nef18 
and Nef33/34) is not shown, because the assumed epitope sequences are 
identical among the 3 subtypes. 
 
effect of point mutations on T-cell recognition could be resolved for all three 
peptides sets as well as for subtype A and D peptide sets in Gag p24. 
 
Does the subtype of the infecting HIV-1 strain influence the peptide-specific 
CD8 T cell recognition? Peptide Gag7 was predominantly recognized by study 
subjects that were infected with a subtype C Gag expressing HIV strain. 3 of 4 
subjects who were exposed to a subtype A Gag expressing strain recognized 
the subtype A variant of Gag45 better than the subtype D variant, wheareas 
only 2 of 8 subjects infected with a C Gag expressing strain recognized the A 
Gag variant better than the subtype D variant (fig. 3.11). Together with the 
observation that the C Gag peptide set was superior for detecting responses in 
the HIV-1 subtype C dominated epidemic in Mbeya region, these results 
suggest that the T cell recognition of variant epitopes is in part dependent on 
the subtype of the infecting HIV strain. However, for some of the analysed 
Gag-specific peptide responses, the subtype of the infecting strain did not 
appear to play a major role on which peptide variant would be recognized with 
the highest frequency of responding PBMC. 
 
 
3.2.5 A minimal set of 15 peptides is recognized by 94% of HIV 
seropositives outside the HISIS cohort 
While no single peptide set was capable of detecting all of these responses 
optimally, a composite peptide pool consisting of peptides representing 
subtypes A, C and D across the immuno-dominant regions would be the best 
configuration to detect HIV-1-specific CD8 T-cell responses in HIV-infected 
subjects in Tanzania. To test this hypothesis, a pool of frequently recognized 
peptides including 10 of the most frequently recognized Gag peptides and 5 of 
the most frequently targeted nef peptides was designed. Responses to these 
peptides were associated with HLA class I alleles common in the Mbeya 
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region. The 15 peptides included in the pool are denoted in Table 1 (frequently 
recognized peptides; FRP-pool). Within the HISIS-CTL cohort, 96% of 
subjects expressed at least one, and 77% expressed two or more alleles known 
to restrict responses to the FRP-pool. The FRP-pool was then tested on 50 HIV 
seropositive and 25 HIV seronegative individuals from two other studies (as 
described in Materials and Methods), outside the HISIS-CTL cohort. The 
ELISPOT assay was performed using 2.5 x 105 PBMC/well and the cut-off 
value was 20 SFC/106 PBMC. Strikingly the FRP-Pool was recognized by 94% 
of HIV seropositives, while it was not recognized by any of the HIV 
seronegative study subjects (fig. 3.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13. A pool of 15 frequently recognized HIV-1 Gag- and Nef-
derived peptides (FRP-pool) was tested for recognition by PBMC from 50 
HIV-1 seropositive individuals arbitrarily chosen from an HIV cohort in 
the same epidemic region as the HISIS-CTL cohort. Study subjects from the 
HISIS-CTL cohort were excluded. To demonstrate assay specificity, 25 HIV 
seronegative individuals were included. Shown are the SFC/106 PBMC for 
each individual. 
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3.3 Infection with multiple HIV-1 strains contributes to a broadening 
Gag-specific CD8 T cell response  
 
In chapter 3.1, evidence was presented that one of the main determinants for 
the immunological outcome of an HIV-1 infection appears to be the HLA 
background of the infected individual. Additional parameters are the duration 
of the infection (Addo et al., 2003; Goulder et al., 2001) and potentially the 
viral diversity within an HIV-infected individual on the HIV-specific CD8 T 
cell response. Infection with multiple HIV strains has been shown to increase 
diversity of viral quasi-species by ongoing inter-strain recombination. This 
resulted in a strong fluctuation of many different molecular forms of HIV-1 
within multiply infected individuals (Gerhardt et al., 2005; McCutchan et al., 
2005). Hence the diversity of the viral quasi-species is increased and, with the 
ever changing molecular recombinant forms, much more dynamic in 
individuals infected with multiple HIV-strains. This in turn is likely to affect 
the HIV-specific immune response, as it will at least transiently be exposed to 
different amino acid variants of the same epitope. Jung et al. have suggested 
that the number of distinct antigenic epitopes presented by a single cell may 
also be increased, thereby broadening immune recognition (Jung et al., 2002). 
 
Only little is known on how the immune system will react to the exposure to 
multiple variants of the same virus. Infection to multiple HIV subtypes might 
induce a broadly cross-reactive immune response, but also could give rise to 
the least immunogenic strain by recombination of the two strains. In one of the 
first reported cases of an HIV-superinfection, Altfeldt et al. have observed i) a 
decreasing frequency and ii) a changing pattern of CD8 T cell epitope 
specificities upon superinfection with a second subtype B virus (Altfeld et al., 
2002; Jost et al., 2002). After inter-subtype superinfections the CD8 T cell 
response appears to adapt to the incoming strain (Ramos et al., 2002; Yang et 
al., 2005). However, there have only been few case studies published on this 
subject so far.  
 
The high proportion of multiply infected study subjects in the HISIS-CTL 
cohort allowed to address the question of how the increased viral diversity in 
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multiply infected individuals affects the HIV-specific CD8 T cell response on a 
population level. This issue was addressed in the 3rd part of this PhD thesis. 
 
3.3.1 Dual infected study subjects add up to 50% of the HISIS-CTL 
cohort 
The MHAacd allows determination of the infecting subtype and to distinguish 
infections with a single HIV strain from infections with multiple HIV strains. 
The subtype distribution of this cohort is described in chapter 3.2. As 
exemplified in figure 3.14, indications for an infection with multiple HIV 
subtypes are i) the binding of probes from 2 or 3 different subtypes to a single 
genomic region in the MHAacd during one or more FUs  or ii) a changing 
pattern of subtype-specific probes that bind to the same genomic region.  For 
example, study subject H123, who seroconverted at the beginning of the study 
(FU1), was first infected an AD recombinant strain and then superinfected 
during FU2 with a different ACD recombinant virus. Study subject H001 is a 
pure subtype C infection, whereas study subject H561 was infected with an AC 
recombinant strain during FU8. In total, the MHAacd results indicate that  50% 
(n=28) of the HISIS-CTL study subjects were infected with more than one HIV 
strain. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 MHAacd patterns of single and multiply infected subjects: 
Shown are the results of the analysis for subtypes A, C and D for the 5 
genomic regions Gag, Pol, Vpu, Env1 and Env2 at multiple follow ups (3 
months intervals). Indications for multiple infection in bold) 
 
 
 
 
H001: single infected
Gag Pol Vpu Env1 Env2
FU0 C C C C
FU1 C C C C
FU2 C C C
FU3 C C C C C
FU4 C C C C C
FU5 C C C C C
FU6 C C C C C
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FU13 C C C C C
H561: inf. with AC-recombinant
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H123: Dual infected
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3.3.2 Infection with multiple HIV strains is associated with a broad Gag-
specific CD8 T cell response 
Infection with multiple HIV strains increases the diversity of the viral quasi-
species and exposes the human immune system to multiple amino acid variants 
of the same HIV protein. Thus it may be hypothesized that infection with 
multiple HIV strains may broaden the HIV-specific T cell response. To test this 
hypothesis, the number of recognized epitopes within Gag and Nef was 
compared in multiply and single infected subjects (fig. 3.15 and 3.16). The 
breadth of the Gag-specific CD8 T cell response was a median of 3 epitopes 
recognized for both multiply and single infected subjects with a range of 0-10 
epitopes recognized in multiply infected subjects and 0-6 epitopes recognized 
in single infected subjects. The mean breadth was 3.6 and 2.8 epitopes 
recognized for multiply and single infected subjects respectively. Of note is 
that 28.6% (8 of 28) of multiply infected subjects recognized 5 or more 
epitopes within Gag, whereas only 10.7% (3 of 28) of single infected subjects 
recognized that many epitopes. Similar differences were observed in the 
recognition of subtype A, C and D Gag-specific peptide pools as shown in 
figure 3.15. 62 study subjects of the HISIS-CTL cohort were tested with 
subtype-specific peptide pools. Each of the 11 peptide pools contains 11 
consecutive overlapping peptides, which subdivide gag into 11 antigenic 
regions: pools number 1A to 3A cover for Gag p17, 4A to 8A cover p24 and 
pools 9A to 11A cover p15. Responses to Gag44/45 and Gag88/89 were 
detected within 2 consecutive pools, but were counted as one pool response 
only, because in both cases the respective response is directed against a single 
epitope: Gag44/45 was counted as a pool 5 response and Gag88/89 as a pool 8 
response. A median of 3 peptide pool responses were detected with subtype C 
Gag peptides within both groups. For the subtype A and D Gag peptides, the 
median number of pools recognized was 2 and 1.5 for multiply infected 
subjects respectively, but only 1 for subtype A and D Gag peptides for single 
infected subjects. With the subtype C peptides, 5 or more peptide pools were 
recognized in 18.8% (n=6/32) of multiply infected and only 6.3% (2 of 32) of 
single infected subjects, corresponding numbers for the subtype D peptides 
were 13.3% (4 of 32) in multiply infected versus 6.3% (2 of 32) in single 
infected subjects and for the subtype A peptides 13.3% (4 of 30) of multiply 
                                                                                             Results 
 74
infected and 0% of the single infected. Hence there was a clear tendency that 
the increased viral diversity of quasi species contributes to a broadening of the 
Gag-specific CD8 T cell response in subjects infected with multiple HIV-1 
strains. 
 
Interestingly the Nef-specific CD8 T cell response appeared to be unaffected 
by the exposure to multiple HIV strains. Both groups had a very similar 
breadth of Nef specific CD8 T cell responses that could be explained by the 
highly focused Nef-specific CD8 T cell response observed in many study 
subjects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 Breadth of the HIV-1 Gag (A) and the HIV-1 Nef (B) specific 
T-cell response in single infected (white bars, n=28) and multiply infected 
(black bars, n=28) study subjects. Shown is the frequency of responders and 
the number of epitopes recognized by the different study subjects is given. 
Responses to 2 consecutive peptides were counted as 1 epitope response. 
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Figure 3.16. Breadth  of  subtype-specific Gag  peptide pool recognition in 
single and multiply HIV-1 infected individuals. The number of subtype A, C or  
D Gag derived peptide  pools recognized by dual infected (n=30, black bars) and 
single infected (n=31, white bars) and the corresponding frequency of responders 
is given.  The  peptide  pools  contained  eleven  successive overlapping peptides. 
Responses against Gag peptides 44/45 and 88/89, which are detected in two pools, 
were counted as a single pool response.
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3.3.3 Infection with multiple HIV-strains may contribute to better cross-
recognition of antigenic regions within p17, p15 and the C-terminal part of 
p24 
Due to the genetic diversity of the HIVpandemic, determination of parameters 
that contribute to T cell cross-recognition of different HIV subtypes has import 
implications for HIV vaccine design. Multi-subtype vaccines have been 
designed and are currently going into phase I/II clinical trials in the near future. 
Studying the CD8 T cell response in single and multiply infected subjects 
allowed addressing the question, whether infection with multiple different 
subtypes may contribute to better cross-recognition of antigenic regions within 
Gag. For this reason, cross-recognition of the 11 subtype A, C and D derived 
peptide pools was analyzed. As shown in figure 3.17A, the percentage of pool 
responses detected with all three peptide sets was 34.5% (40 of 116 analyzed 
responses) for multiply infected subjects and 23.1% (25 of 108 analyzed 
responses) for single infected subjects. To determine whether this difference in 
cross-recognition is seen throughout the whole Gag protein or whether this 
difference in cross-recognition is restricted to particular regions within Gag, it 
was next analysed which peptide pools were recognized within all three 
peptide sets. As shown in figure 3.17B it is mainly p17, the C-terminal region 
of p24 and p15 that contribute to this difference. 6 of 9 peptide pools are cross-
recognized better by multiple infected study subjects, while for 3 peptide pools 
the differences were marginal. This results suggests that cross-recognition of 
antigenic regions is improved in subjects infected with multiple HIV strains. 
 
  
 
Figure 3.17. Cross-recognition of Subtype A-, C- and D-Gag peptide pools in dual 
and single infected study subjects. (A) Shown is the percentage of total analysed pool 
responses for each group (dual, n=116 / single, n=107). (B) Shown are the individual 
peptide pool responses that were detected with all three peptide sets. The y axis shows the 
percentage of total analysed pool responses for dual infected (black bars) and single 
infected (white bars).
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3.3.4 Frequently recognized Gag peptides are targeted by both single and 
dual infected subjects 
Finding immune correlates of protection from infection is an important task for 
HIV vaccine design. In the context of the HISIS-study one important goal was 
the identification of CD8 T cell epitopes that may protect from superinfection. 
For this reason the most frequently recognized antigenic regions were 
examined for recognition by single and multiply infected study subjects. As 
shown in table 3.2, each of the frequently recognized antigenic regions within 
Gag was targeted by both, single and multiply infected study subjects.  
 
Three peptide responses were somehow remarkable: Responders to Gag5 had a 
low median viral load of 23.000 RNA copies/ml. Apparently 5 of the 7 
responders were recent seroconverters (seroconversion < 3.5 years), suggesting 
that this response may be lost in the course of chronic HIV infection. 6 of the 8 
Gag36 responders with an HLA B5703 or B5802 restricted response against 
the epitope ISPRTLNAW were single infected. Median viral load of Gag83 
responders was only 15.800 RNA copies/ml, but still 6 of 8 subjects were 
multiply infected. This observation does not argue in favour of a “protective” 
role of this particular peptide response. 
 
Table 3.2. Recognition of individual Gag peptides by multiply and single infected subjects and median viral load
number of number of median N° of subjects
Peptide# Sequence multiply infected single infected  Viral Load seroconverting
responders responders (RNA copies/ml) < 3.5 years
Gag5 EKIRLRPGGKKKYRL 4 3 23300 5 of 7
Gag7 GKKHYMLKHIVWASR 6 5 266000 1 of 11
Gag20 SLYNTVATLYCVHEK 8 5 197600 4 of 13
Gag35 GQMVHQAISPRTLNA 6 3 158000 5 of 9
Gag36 HQAISPRTLNAWVKV 2 6 92600 3 of 8
Gag45 TPQDLNTMLNTVGGH 13 10 158000 8 of 23
Gag50 MLKDTINEEAAEWDR 3 3 221000 1 of 6
Gag72 GPKEPFRDYVDRFFK 3 3 708000 3 of 6
Gag74 YVDRFFKTLRAEQAT 6 6 110250 5 of 12
Gag76 LRAEQATQEVKNWMT 3 3 182700 1 of 6
Gag83 TILRALGPGATLEEM 6 2 15800 3 of 8
Gag88 ACQGVGGPSHKARVL 6 3 74300 3 of 9
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4. Discussion 
 
 
4.1 Identification of a CD8 T cell mediated mechanism that contributes 
to the maintenance of a low viral load steady-state level 
One of the main objectives of the HISIS-CTL study was to clarify determinants 
of the anti-viral efficiency of the HIV-specific CD8 T cell response and to 
examine the influence of the expression of HLA class I alleles on the HIV-
specific CD8 T cell response. 
The results of the HISIS-CTL study are best understood in the context of the 
study of Kiepiela et al. Frequency of HLA alleles and the associated respective 
median viral load closely matched that observed in the Kiepiela study (Kiepiela 
et al., 2004). Nonetheless, the median viral load among the HISIS-CTL study 
subjects was more than 5 fold higher than the median viral load observed in the 
Kiepiela study. Study subjects from both studies did not receive antiretroviral 
treatmenr (ARV). Other comparable studies conducted in the US, in Zambia or 
in South Africa also reported much lower median viral loads than that observed 
in the HISIS-CTL cohort, with median viral loads of ~18 000, 37 000 and 11 
500 RNA copies/ml respectively (Mellors et al., 1996; Novitsky et al., 2003; 
Masemola et al., 2004). The protocol used to determine the plasma viral load 
was identical for the Kiepiela and the HISIS-CTL study and was approved by 
the U.S. Food and Drug Administration (FDA). Thus technical reasons for the 
observed difference can be excluded. 
 
Grobler et al. have observed a significantly higher viral load set point in 4 
dually infected subjects compared with 15 single infected subjects (Grobler et 
al., 2004), indicating that the high proportion of multiply infected subjects 
within the HISIS-CTL study could be a reason for the high viral load observed. 
However, in the HISIS-CTL study there was no difference in the viral loads of 
multiply and single infected subjects.  
 
The most likely reason for the high median viral load of the HISIS-CTL study 
could be longer infection times. It is known that late in the course of HIV 
infection plasma viral levels rise (see introduction fig.1.6). 33 subjects were 
infected for more than 3.5 years while 22 study subjects seroconverted during 
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the last 3.5 years. These seroconverters had a median viral load of 40 600 RNA 
copies/ml at 24 months past seroconversion, which is in the range observed in 
most other studies. Therefore the high median viral load observed in within the 
HISIS-CTL cohort is likely to reflect a high proportion of subjects who have 
been infected for extended time periods. 
 
HLA class I restricted CD8 T cell is thought to play a key role for containing 
viral replication. They are likely to contribute to the decline of plasma viremia 
during acute infection and to the establishment and to the maintenance of the 
steady-state virus level during chronic infection (Borrow et al., 1994; Koup et 
al., 1994; Masemola et al., 2004; Novitsky et al., 2003; Ogg et al., 1998). 
However, it is not completely understood, why the disease in some individuals 
progresses rapidly even in the presence of a strong CD8 T cell response, but 
not in others. Various studies have not found any correlation between the CD8 
T cell response and viral load (Addo et al., 2003; Cao et al., 2003; Frahm et al., 
2004) or even found a positive linear relationship of the frequency of Nef- or 
Env-specific CD8 T cells and the plasma viral load (Betts et al., 2001). 
Because of these difficulties to clearly define parameters important for an 
efficient HIV-1-specific CD8 T cell response in HIV-infected humans, the 
most conclusive data about the importance of the HIV-specific CD8 T cells is 
derived from the SIV-Rhesus Macaque model. In experimental SIV infection, 
depletion of CD8 T cells leads to a transient rise in SIV plasma viremia and 
loss of CD4 T cells until the CD8 subset recovers (Jin et al., 1999; Schmitz et 
al., 1999). 
 
A different way of looking at parameters affecting the HIV-specific CD8 T cell 
response is to study the restricting elements for CD8 T cell recognition of HIV 
- the HLA class I alleles. Kiepiela and collegues found that i) viral load, 
absolute CD4 cell counts and the rate of disease progression was strongly 
associated with particular HLA B alleles and ii)  that HIV-1 specific CD8 T 
cell responses were mainly restricted by HLA B alleles (Kiepiela et al., 2004). 
HLA-B alleles associated with a beneficial effect during HIV-1 infections were 
B4201, B57, B5801 and B8101 whereas B5802, B18, B4501 were associated 
with a high viral load. With the exception of HLA B 4201, the HLA allele/viral 
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load associations observed in the HISIS-CTL study closely match those 
reported in the Kiepiela study. However, in contrast to the Kiepiela study, HLA 
B4201 expression was not associated with a low viral load. 
 
The data presented in chapter 3.1 may provide a link between the expression of 
the HLA class I alleles B0702, B5801 and B8101, and a particular “protective” 
pattern of CD8 T cell epitope recognition observed in subjects expressing these 
HLA alleles. So far nobody has elucidated the mechanism underlying the 
beneficial effect of particular HLA alleles during HIV infection (Walker and 
Korber, 2001).  The targeting of multiple epitopes within the Gag regions 
aa001-aa075 (GagR1) and aa248-aa500 (GagR3) appears to play a major role 
for efficient control of HIV viral replication over extended time periods. 
Another interesting observation was that co-expression of HLA alleles B8101 
with B0702 or B5801 appeared to strengthen the relationship of these alleles 
with a very broad epitope recognition pattern within whole Gag and GagR1R3 
and a low viral load. Contrary, co-expression of non-protective HLA-alleles, 
such as B5802, B4501, B1510 or B5301 was not associated with broad 
recognition of epitopes within GagR1R3, but instead with a 30x higher median 
viral load. This result together with the strong inverse linear relationship 
observed between the number of epitopes recognized within GagR1R3 and the 
viral load suggests that the antiviral effect of the CD8 T cell response is in part 
predictable by the number of epitopes recognized within this region.  
 
How can we exclude the possibility that the recognition of multiple epitopes 
within GagR1R3 is a mere reflection of an early stage of HIV infection? As 
shown in figure 3.6, the recognition of multiple GagR1R3 epitopes during the 
chronic phase of HIV-1 infection was strongly associated with a low median 
viral load set point during the early phase and the maintenance of a low steady-
state level of plasma virus during the chronic phase of HIV-1 infection. With 
the exception of two HLA B57 expressing subjects, none of the subjects that 
did not target multiple epitopes within GagR1R3 significantly reduced primary 
plasma viremia. The high viral load set-point and steady state viremia persists 
in these subjects in the absence of an efficient CD8 T cell response. These 
results indicate that the differences in the viral load set point and steady-state 
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level seen among HIV-infected individuals is strongly dependent on the quality 
of the HIV-specific CD8 T cell response. The viral load steady state-level has 
been shown to predict the rate of disease progression (Mellors et al., 1996). 
Therefore the breadth of GagR1R3-specific CD8 T cell response may in part 
predict the rate of disease progression. 
 
Differences in the CD8 T cell recognition pattern between subjects with or 
without efficient viral control were greatest within the C-terminal region of 
Gag p24 and p15 (GagR3) followed by N-terminal p17 (GagR1). It is possible 
that Gag regions R1 and R2 contain protein domains, whose function may 
easily be disrupted by point mutations. For example p17 is important for 
recruitment of p24 to the budding site and therefore has to interact with p24 
and with cytoplasmic tail of gp41.  The C-Terminal region of p24 together with 
p2 are essential for proper assembly of the RNP shell (Zhang et al., 1996) and 
are crucial for HIV morphogenesis (Gottlinger et al., 1989; Krausslich et al., 
1995; Pettit et al., 1994); p10 for effective encapsidation of the viral genome 
(Bess, Jr. et al., 1992; Clavel and Orenstein, 1990; Gorelick et al., 1990) and 
effective virus assembly (Jowett et al., 1992) and p6 is essential for the last 
steps of viral budding (Gottlinger et al., 1991). These results indicate that 
targeting of multiple epitopes located in Gag regions important for several 
steps of viral morphogenesis may be associated with high antiviral efficiency. 
 
A changing pattern or loss of epitope recognition in the course of HIV-1 is 
common and can deteriorate the antiviral efficiency of the CD8 T cell response 
(Goulder et al., 1997). Escape from CD8 T cell recognition during the acute 
phase has been shown to be a hallmark of SIV infection. (O'Connor et al., 
2002). However, targeted HIV-epitopes vary in their susceptibility to point 
mutation (O'Connor et al., 2002) and therefore CD8 T cells of different 
specificities may have very different long term affects. Therefore loss of 
GagR1R3 epitope recognition or exhaustion of GagR1R3 epitope-specific CD8 
T cells is likely to contribute to disease progression. However, viral escape 
from the GagR1R3 specific CD8 T cell response may be deleterious to the viral 
fitness, because mutations within these regions might prevent virus assembly. 
This interpretation is supported by the finding that HLA-associated HIV 
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sequence polymorphisms are much more often observed in the genes encoding 
for Nef, Tat and Vif than for the proteins encoded in the gag gene (Kiepiela et 
al., 2004). In the SIV/Rhesus macaque model, escape from a Tat-specific CD8 
T cell response is much more rapid than escape from a Gag response 
(O'Connor et al., 2002), a finding supported by Jones and colleagues in HIV-1 
infection. 71% of the HIV-1 Tat epitope responses selected escape variants, 
whereas only 26% of Gag-specific responses selected such mutants in a similar 
time frame (Jones et al., 2004). Additional data supporting this view can also 
be derived from an in vitro system to determine HIV-1 mutational escape from 
cytotoxic T cells. It was demonstrated that escape from Nef-specific CD8 T 
cell responses was more rapid and more consistent than escape from Gag-
specific responses (Yang et al., 2003a). Therefore functional constraints may 
hamper the rapid escape of HIV-1 from CD8 T cells targeting epitopes within 
GagR1R3.  
 
A different explanation could be that exhaustion of HIV-specific CD8 T cells 
may in part be dependent on epitope specificity and avidity of the T cell 
receptor. CD8 T cells recognizing epitopes within GagR1R3 would be less 
prone to exhaustion and hence display a preserved functionality. A declining 
cytotoxicity of HIV-specific responses was observed in two studies despite 
persistent recognition of autologous epitopes of the infecting virus (Draenert et 
al., 2004b; Koibuchi et al., 2005). 
 
A broad recognition of epitopes within the Gag regions R1 and R3 appears to 
be of particular importance for an efficient control of viral replication. In 
contrast to the antiviral efficiency of the Gag-specific CD8 T cell response, the 
breadth of Nef or Env epitope recognition did not appear to be of major 
importance for viral control. Interestingly, an opposite trend for the Nef-
specific T cell response compared to the Gag-specific response was observed 
in this work. A similar relationship of the Nef-specific T cell responses with a 
higher viral load has also been observed in other studies (Betts et al., 2001; 
Masemola et al., 2004; Novitsky et al., 2003). These differences in antiviral 
efficiency between the Gag- and Nef-specific responses indicate that T cell 
specificity plays a role in determing functionality of a CD8 T cell. In vitro 
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antiviral activity of CTL clones varies in dependency of epitope specificity 
(Yang et al., 2003b). A recent report suggested that Nef-mediated HLA Class I 
down regulation may in part dependent on the epitope presented and that Nef 
can modifiy the antiviral efficiency of CD8 T cells of different specificities 
(Tomiyama 2005, JI).  
 
That the Gag-specific CD8 T cell response may play a special role in slowing 
down progression to AIDS was first shown in 1995 (Riviere et al., 1995) and 
numerous more recent studies supported this finding (Edwards et al., 2002; 
Masemola et al., 2004; Novitsky et al., 2003; Ramduth et al., 2005).  However, 
most of these studies found that a high frequency of Gag-specific CD8 T cells 
is associated with efficient control of viral replication (Novitsky et al., 2003; 
Ogg et al., 1998), a finding not supported by the HISIS-CTL study. Two 
studies, the Masemola and the Ramduth study, found a significantly lower viral 
load in individuals who preferentially targeted the Gag protein (indicated by a 
frequency of Gag-specific CD8 T cells compared to other HIV proteins) 
(Masemola et al., 2004; Ramduth et al., 2005). One possible explanation for 
these different observations could be that the frequency of HIV-specific CD8 T 
cells is to some degree reflective of the number of epitopes targeted (Addo et 
al., 2003). That both parameters, the breadth and the frequency of the Gag-
specific T cell response, correlate with a low viral load has been found by 
Edwards and colleagues and provides a link between our findings and those of 
the other studies concerning the anti-viral effect of the Gag-specific T cell 
response (Edwards et al., 2002; Masemola et al., 2004; Novitsky et al., 2003; 
Ramduth et al., 2005).  The data presented in this PhD thesis suggests that the 
breadth and specificity of the HIV-specific CD8 T cell response is a major 
determinant of the antiviral efficiency, but not the frequency of all Gag-specific 
CD8 T cells. In our HISIS-CTL study an inverse linear relationship between 
the GagR1R3-specific CD8 T cell frequency and the viral load was found.  
 
What other factors could contribute to differences in antiviral efficiency? The 
breadth of CD8 T cell recognition can play a role in the containment of HIV 
during chronic HIV infection (Chouquet et al., 2002). This effect may be 
explained by a study that suggested that escape from T cell recognition is less 
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likely in the presence of a broad HIV-specific T cell response (Jones et al., 
2004). Interestingly, Gag is the dominant target of the HIV-specific CD4 T cell 
response (74% of HIV-specific CD4 T cells target the Gag protein, (Ramduth 
et al., 2005), which theoretically could contribute to an efficient Gag-specific 
CD8 T cell response due to good support by Gag-specific CD4 T cells. After 
restimulation with virus like particles (VLP Pr55, subtype B), we did not find 
any association of the Gag -specific CD4 T cell response with the GagR1R3-
specific CD8 T cell response and in general found relatively low frequencies of 
Gag-specific CD4 T cells that were predominantly secreting IFNγ. The 
frequencies of IL-2 secreting CD4 T cells were very low. However, it is 
possible that subtype B VLPs are not the optimal stimulants to detect CD4 
responses in subjects infected with non-B subtypes. 
 
Targeting of particular Gag epitopes is not the only way to efficiently control 
viral replication. No evidence indicated HLA B57 mediated recognition of 
multiple epitopes within Gag or GagR1R3. Nonetheless B57 was associated 
with a relatively low median viral load (fig 3.1). Hence the antiviral 
determinant of HLA B57 restricted CD8 T cell responses is likely to differ 
from the mechanism described above. This hypothesis is supported by 
Migueles and colleagues, who found comparable Gag-specific CD8 T cell 
responses in HLA B57 expressing Long-Term Non-Progressors (LNTPs) and 
progressors (Migueles et al., 2003). The fact that 89% of the study subjects 
with a viral load below 50 000 RNA copies/ml recognized 2 epitopes 
emphasizes the importance of mechanism for maintaining a low viral load and 
a high CD4 cell count. However, in contrast to HLA B57 expression or a 
homozygous deletion in the CCR5 coreceptor gene that only affect a small 
minority of individuals, the recognition of multiple GagR1R3 epitopes 
contributes to efficient viral control in most individuals with maintained low 
viral loads and therefore the latter observation is of general importance on a 
population level.  
 
The individual HLA class I background largely determines, which peptides can 
be presented to CD8 T cells. The finding that certain HLA alleles like B57 or 
B5801 are associated with long-term non-progression, whereas other alleles, 
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such as B5802, are associated with more rapid disease progression indicates 
that protective HLA alleles enable for a particularly effective CD8 T cell 
response (Carrington et al., 1999; Kaslow et al., 1996; Kiepiela et al., 2004; 
Migueles et al., 2000). However, a direct relationship between the expression 
of “protective” HLA alleles and an efficient CD8 T cell response has not been 
demonstrated by any of these previous studies. The capacity for the 
presentation of GagR1R3 epitopes appears to be strongly affected by the HLA 
molecules expressed by one individual. Therefore the HLA background 
appears to be one of the main determinants enabling a broad epitope 
recognition within Gag. One central question arising at this point is what 
causes this difference in the epitope presentation pattern of the “protective” 
HLA alleles B0702, B5801 and B8101. The sequence binding motif for 
“protective” HLA alleles may enable the presentation of a much broader 
variety of epitopes as suggested by Nelson GW et al (Nelson et al., 1997). 
Experimentally we have found that 7 of the 10 most frequently recognized 
epitopes within the Gag protein were presented by these alleles. Contrary it 
was only 3 recognized epitopes for the “non-protective” alleles, such as B1510, 
B4501 and B5802. In line with Nelson et al, I have found only a limited 
number of predicted epitopes within Gag in general, but especially within 
GagR1R3 for B5802 and B1510.  
 
Another possible determinant for the antiviral efficiency of a CD8 T cell 
response could be a high variability among recognized eoitopes, allowing the 
virus to easily escape recognition. 47 Gag protein sequences from all predicted 
epitopes for both “protective” and “non-protective” were aligned and the 
degree of amino acid variation was determined for each position (data not 
shown). There was no evidence to support this hypothesis.  
 
One interesting observation is that often 2-3 predicted epitopes restricted by 
HLA-B5801 are clustering in very close proximity to each other – often 
sharing one of the anchor residues (exemplified in fig. 4.1). Practically this 
could be an advantage: If recognition of an epitope would be lost due to 
mutational escape of one anchor residue, the second epitope could replace the 
primary response within the same region. A similar phenomenon has also been 
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described for 2 HLA B57 presented epitopes, one of which was entirely 
contained within the other (Goulder et al., 2000). Further indication that a 
relatively similar hypothetical mechanism may play a role can be derived from 
the fact that 3 subjects co-expressing HLA B0702 and B8101 have a low viral 
load (<29 500 RNA copies/ml). Some epitopes within Gag are restricted by 
both B0702 and B8101 and the predicted anchor residues of these two alleles 
are identical capacity (Marsh et al., 2000; Yusim K et al., 2004). One might 
hypothesize that targeting of the same epitope by two different HLA-alleles 
also minimizes the potential for HIV to escape this CD8 T cell response. 
Therefore targeting of the same epitopic region by CD8 T cells of slightly 
different specificity might contribute to the anti-viral efficiency of a HIV-
specific CD8 T cell response.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Clustering of predicted epitopes for HLA-B5801. Shown is the 
Gag region aa153 – aa178 and predicted HLA B5801 epitopes (red bars) 
Epitope prediction was based on the motif x-[AST(G)]-x-x-x-x-x-[FW(Y)] 
(SYFPEITHI Database). Potential anchor residues in 2nd position are colored 
red and blue for the C-terminal anchor residues. The variability index is 
calculated by dividing the number of amino acid substitutions by the number of 
aligned sequences (n=47) and multiplying the results by 100. 
 
 
The Kiepiela study is emphasizing the effect of “protective” HLA alleles on 
human (and viral) evolution. In this context, our data strongly suggests that the 
advantage to have “protective” HLA alleles, with the exception of HLA B57, is 
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dependent on their capability to enable the CD8 T cell targeting of multiple 
regions within GagR1R3 in particular. Of further interest is that a high plasma 
viral load is associated with increased mother to child transmission in HIV 
infected pregnant women (Dickover et al., 1996; Mayaux et al., 1997; Pancino 
et al., 1998). Those who control HIV replication due to CD8 T cells are less 
likely to transmit the virus perinatally. In fact inheriting HLA genes enables 
human kind to pass on a “protective pattern” of T-cell recognition in the face of 
a viral epidemic. This possibility is not given for B cells and the humoral 
immune response. Contrary Kiepiela and collegues have reported an 
accumulation of  “non-protective” HLA-alleles in HIV positive children born 
by HIV infected mothers (Kiepiela et al., 2004). Inheritability of the HLA 
genes in combination with the somatic rearrangement of the T cell receptor 
genes therefore may actually be crucial in the face of a viral epidemic with the 
potential to wipe out large parts of the human population. Additionally the 
differences found between the CD8 T cell response restricted by “protective” 
HLA alleles and non-protective HLA-alleles stresses the importance of the 
polymorphism found within the HLA genes. Furthermore the findings of the 
HISIS-CTL study strongly support the idea that the evolution of the HLA class 
I gene locus is driven by the relationship of the CD8 T cell response and 
endemic pathogens.  
 
In the absence of antiretroviral therapy  it is possible that HLA allele mediated 
CD8 T cell pressure is attenuating the virus as well (Brander and Walker, 
2003) and may lead to “coexistence” of HIV and the human population in the 
future, similar to SIV in their respective natural hosts. Furthermore one might 
speculate that other persistent viruses that now coexist “peacefully” with the 
human host, such as CMV and to a lesser degree Hepatitis B and C, may have 
been much more destructive in the human host initially and drove the evolution 
of the human HLA gene locus. This may give individuals expressing 
“protective HLA alleles” a selective advantage in the face of a viral epidemic 
and might therefore also be a major force of human evolution in general. ` 
 
However, with the advent of anti-viral drugs, this role of the HLA genes on 
human evolution may be replaced by a rather cultural mode of evolution, 
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where other (non-molecular) factors play a more dominant role i.e. education, 
sexual behaviour, financial status of the individuum or else. In this aspect the 
human kind clearly differs from other animals. 
 
4.2 Cross-recognition of HIV epitopes 
Because of the extensive genetic variation of HIV, the identification of 
conserved, cross-reactive epitopes is a key element in HIV vaccine 
development. The study described here was designed to  characterize CD8 T 
cell responses in an East African cohort of HIV-1 seropositive individuals in a 
mixed-subtype environment, and to better define optimal immunogenic peptide 
sets. In concordance with other studies, certain regions of Gag and Nef were 
recognized by a high frequency of study subjects. Many of the 
immunodominant regions detected during the HISIS-CTL study match 
frequently targeted antigenic regions from studies conducted with individuals 
from different ethnic groups and with peptides based on HIV-1 subtypes B and 
C (Addo et al., 2003; Frahm et al., 2004; Masemola et al., 2004; Novitsky et 
al., 2002). This suggests that the pattern of immunodominant regions within 
gag and nef is comparable across many HLA backgrounds and among diverse 
HIV-1 subtypes in different regions of the world. It will simplify HIV-1 
vaccine design if many of the same epitopes are targeted in multiple HLA 
backgrounds and across many HIV-1 subtypes, because these regions can be 
specifically selected for vaccine antigens. Additionally, several new 
HLA/epitope associations were detected (Table 3.1) that will facilitate 
subsequent research on vaccine design and evaluation in the region of Mbeya.  
 
Interestingly, the subtype of the infecting strain and the recognition of subtype 
specific peptide were not necessarily associated. Only for Gag7 we did find 
that predominantly subtype C Gag exposed subjects were mounting a response. 
For Gag45 the subtype A peptide variant was usually recognized better in 
subtype A exposed subjects than in subjects exposed to HIV-1 C or D. There 
was no strong association between the infecting subtype and the CD8 Tcell 
recognition of subtype-specific peptides.  
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Complete cross-recognition of subtype A, C and D peptides, i.e. the same 
number of responders with a similar magnitude response was seen only for 
completely conserved epitopes. Amino acid substitutions within epitopes were 
capable of dramatically decreasing or completely abrogating the frequency and 
magnitude of detected responses. Interestingly, for most of the studied 
antigenic regions the majority of responders always recognized the three 
different peptide variants in a similar fashion, while a small minority of 
responders differed in their pattern of subtype A, C and D variant recognition. 
This pattern was independent of the restricting HLA-allele. These findings and 
previously published reports (Charini et al., 2001; Haas et al., 1996), suggest 
that minor sequence variation within epitopes, some of which may be subtype-
associated or subtype specific, can influence the ultimate breadth of the CD8 T 
cell response that is generated. This concept, in the context of different HLA 
backgrounds and HIV-1 subtypes, would suggest that the optimal HIV-1 
vaccine may not be one based on a single subtype, but either one based on 
multiple subtypes or one that could contain epitopes from multiple subtypes 
that generate the most broadly cross-reactive response. 
 
Despite the remarkable degree of flexibility and adaptability of the HIV-
specific T-cell response (Boissonnas et al., 2002; Buseyne et al., 2001; Haas et 
al., 1996), the initial encounter with antigen may play a critical role in the 
subsequent response to antigenic variants (Klenerman and Zinkernagel, 1998), 
including those developed against the viral quasispecies within an individual 
and upon re-exposure to a different HIV-1 strain or subtype. HIV dual and 
superinfections are being described with increasing frequency (Altfeld et al., 
2002; Gerhardt et al., 2005; McCutchan et al., 2005), and it is possible that the 
specifics of the response to the initial infection may influence susceptibility to 
re-infection. Unfortunately even a broad and specific T cell response does not 
guarantee protection from HIV superinfection (Altfeld et al., 2002). 
 
A further important result of the described study for immune assessment 
laboratories is the limited extent of complete cross-recognition between peptide 
sets based on subtypes A, C, and D. As Figure 2B highlights, only 56 of 180 
pool responses were detected regardless of which peptide set was used, and no 
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two peptide sets substituted for the combination of the three. The observed 
superiority of the subtype C Gag peptide set for detecting T-cell responses is 
likely to reflect the predominance of HIV-1 subtype C and C-containing 
recombinants in the population studied. In addition, the location of the epitope 
within some C Gag 15mer peptides may be favourable for stable binding of the 
peptide to the HLA molecule. Despite identical amino acid sequences of the 
epitopes, the C Gag peptides Gag45, Gag50, and Gag76 were recognized with 
a much higher magnitude than the corresponding A or D Gag peptides. 
Interestingly, subtype C Nef peptides had no obvious advantage for detecting 
Nef-specific responses if compared with subtype A and D Nef peptide sets. In 
fact all of the responses against epitopes outside the central region of Nef were 
only detected with either subtype A and/or D Nef peptide sets.  
 
Some previous studies have highlighted the “frame-of-epitope” effect, in which 
the position of a minimal 9- or 10-mer epitope within a 15-mer peptide can 
have a profound effect on the magnitude of the T cell response (Beattie et al., 
2004; Draenert et al., 2004a). In the HISIS-CTL study the C Gag peptide set 
was offset relative to both the A Gag and D Gag peptide sets due to a 3 amino 
acid deletion of the C Gag sequence at the beginning of p24.  
 
A composite pool of 15 peptides covering the most frequently recognized 
epitopes was designed and tested. This optimal pool mostly contained subtype 
C derived peptides, but required the inclusion of peptides from subtypes A and 
D as well. The success of this pool in detecting CD8 T cell responses within a 
regional epidemic (94% of subjects tested positive, with no false positives), 
signifies that this approach may be a practical solution to the problem 
screening for vaccine generated CD8 T cell responses from samples of limiting 
cell quantities, serving as the best single reagent for this population. A further 
advantage of this pool of frequently recognized peptides is that it includes 
many antigenic regions that are recognized within different ethnicities and 
HIV-epidemics (Addo et al., 2003; Frahm et al., 2004; Masemola et al., 2004; 
Novitsky et al., 2002). The quest for a broadly protective HIV-1 vaccine has 
been frustrated by obstacles at many levels. Problems inherent in host and viral 
variability, selection and evaluation of appropriate vaccine trial cohorts, and 
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laboratory assays for the measurement of immune responses are being 
addressed and, to varying degrees, overcome. The strengths of systematic 
evaluations of T cell responses, supported by host and viral genotypes and 
conducted with more optimal laboratory reagents, are apparent from this and 
other studies.  
 
4.3 Increased viral diversity is associated with a broadening of Gag-
specific CD8 T cell responses 
Infection with more than one HIV-1 strain has recently become a focus in HIV 
research. Infection with multiple strains is followed by an increased diversity 
of viral “quasispecies” and causes a significant fluctuation in molecular 
recombinant forms of HIV-1 (Gerhardt et al., 2005; McCutchan et al., 2005). 
Furthermore infection with multiple viral strains is associated with a higher 
viral load set point and rapid disease progression (Gottlieb et al., 2004; Grobler 
et al., 2004). However, the effect that dual infection might have on the HIV-
specific CD8 T cell response has been studied in 5 superinfected individuals 
only (Altfeld et al., 2002; Jost et al., 2002; Ramos et al., 2002; Yang et al., 
2005). The HISIS study was designed to systematically evaluate intersubtype 
dual and superinfections in a large high-risk cohort.  During the HISIS-CTL 
study the Gag and Nef specific CD8 T cell response of 56 HIV-infected 
subjects was analyzed, half of them infected with more than one HIV strain. 
This allowed addressing the question, whether the increased diversity of viral 
“quasi species” within multiply HIV-1 infected individuals affects the HIV-
specific CD8 T cell response. 
 
One interesting question is whether many of the multiply infected subjects 
were in fact superinfected at some timepoint. Superinfection has been shown to 
be relatively rare if compared to coinfection with multiple HIV-strains 
(Gottlieb et al., 2004; Grobler et al., 2004). Gonzales et al did not detect any 
case of superinfection in 718 individuals (Gonzales et al., 2003). In the HISIS-
CTL study no distinction between superinfection and co-infection was done, 
except for subject H123 (McCutchan et al., 2005). Based on the findings of 
Gottlieb, Grobler and Gonzales, it can be assumed that the majority of the 
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multiply infected subjects in the HISIS-CTL study were coinfected with 
different HIV-1 strains. 
 
In the HISIS-CTL study, infection with multiple strains appeared to broaden 
the Gag-specific CD8 T cell response in many, but not all subjects. A 
broadening CD8 T cell response could be explained by the increased viral 
diversity observed in cases of multiple HIV-1 infection (Gerhardt et al., 2005; 
McCutchan et al., 2005). This finding further emphasizes the flexibility of the 
CD8 T cell response, which seems to adapt upon exposure to multiple HIV-1 
strains. It has been observed before that sequence mutations in targeted 
epitopes during the course of HIV-infection are followed by adaptation of the 
CD8 T cell response (Feeney et al., 2005; Haas et al., 1996). So far the HIV-
specific CD8 T cell response has only been studied in superinfected 
individuals. In these cases a changing pattern of CD8 T cell epitope recognition 
has been reported, with some newly emerging and some disappearing 
responses (Altfeld et al., 2002; Jost et al., 2002; Ramos et al., 2002; Yang et 
al., 2005).  
 
One interesting observation in the HISIS-CTL study is that the distribution of 
subjects with a certain breadth of epitope recognition within Gag differs 
between the two groups. While this distribution within single infected subjects 
is almost a Gaussian distribution, it appears to be skewed towards a broadening 
T cell response in multiply infected subjects. 8 of 11 subjects with a very broad 
Gag-specific CD8 T cell response were infected with multiple strains and most 
of these control viral replication over extended time periods. At the same time 
many of these subjects expressed “protective” HLA alleles B5801, B8101 or 
B0702, indicating that the capacity for a broadening CD8 T cell response in 
multiply infected individuals may in part be dependent on the HLA class I 
background. Nonetheless it would be interesting to see, whether infection with 
multiple strains could in some cases be beneficial. This point of view would be 
against the “doctrine” that infection with multiple strains is rather associated 
with a high viral load set point and rapid disease progression (Gottlieb et al., 
2004; Grobler et al., 2004). In the only confirmed case of superinfection in the 
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HISIS-CTL study, the viral load decreased after superinfection (subject H123, 
described in (McCutchan et al., 2005). 
 
In multiply infected subjects cross-recognition of subtype A, C and D derived 
peptide pools appears to be enhanced, particularly in Gag regions less 
conserved, namely the p17 matrix protein, p15 and the C-terminal part of p24. 
This finding is noteworthy as CD8 T cell targeting of these regions are 
important to maintain control over HIV replication during the chronic phase of 
infection and possibly contribute to a reduced viral load set point (chapter 3.1, 
4.1).  
 
For the development of HIV-1 vaccines that are based on the induction of CD8 
T cell responses, the human diversity of the HLA Class I alleles may prevent 
achieving equivalent and “protective” CD8 T cell responses on a population 
level, a problem not met by “traditional” vaccines that usually rely on the 
induction of neutralizing antibodies. The finding that infection with multiple 
HIV-1 strains broadens cross-recognition of different subtypes emphasizes the 
possible benefit of multi-subtype vaccines. Inclusion of multi-subtype variants 
in vaccines may maximize breadth of the HIV specific T cell response 
independent of the HLA-background of the vaccinees, an effect that would be 
highly desirable.  
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                                                                                                      Summary  
5. Summary 
The importance of HLA class I restricted CD8 T cell response in the control of 
HIV infection is generally accepted, yet few studies have shown a correlation of 
the CD8 T cell response with markers of HIV disease progression. Disease 
progression is dependent on several factors such as the virus load at set-point, 
rarely occurring mutations in the HIV co-receptor genes or the HLA class I alleles 
expressed by an HIV infected individual. It has been shown previously that 
particular HLA class I alleles are associated with a low plasma viral load. 
However, a relationship between these “protective” HLA class I alleles and an 
efficient HIV-specific CD8 T cell response has not yet been demonstrated. In 
order to study the mechanism underlying the beneficial effect of “protective” HLA 
class I alleles, 53 HIV-1 seropositive individuals from a high-risk cohort in 
southwest Tanzania were HLA-typed and the plasma viral load and CD4 counts 
were determined. The recognition of CD8 T cell epitopes within Gag, Nef and Env 
was analysed using a gamma interferon ELISPOT assay and freshly isolated 
peripheral blood mononuclear cells (PBMC).  
 
Gag and Nef were frequent targets of the HIV-specific CD8 T cell response with a 
median recognition of 3 Gag, 2 Nef and 1 Env epitopes per individual. The HLA 
class I alleles B5801, B8101 and B0702 were associated with a low median 
plasma viral load. At the same time expression of these correlated with a broader 
recognition of Gag epitopes (P = 0.0035), if compared with all other common 
HLA class I alleles. Further analysis of the Gag-specific T cell response revealed 
an inverse linear relationship between the number of Gag epitopes recognized and 
the plasma viral load (R = -0.36, P = 0.0016). Particularly, recognition of multiple 
epitopes within two regions of Gag (aa001-aa075 and aa248-aa500) was strongly 
associated with the maintenance of a low viral load, indicating that this pattern of 
HIV-specific CD8 T cell recognition is important for the control of viral 
replication during the chronic phase of HIV infection.  
 
In the second part of the present work, recognition of Gag and Nef variant epitopes 
was analysed using HIV-1 subtype A, C and D derived peptides. 83% of the Gag-
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specific responses were detected with subtype C derived peptides, whereas only 
51% and 57% of responses were detected with subtype A or D peptides, 
respectively. The superiority of the subtype C Gag peptides for detecting CD8 T 
cell responses may in part reflect the predominance of subtype C and C-containing 
recombinant HIV-1 strains within the studied cohort. Nonetheless, screening for 
CD8 T cell responses with any one subtype-specific peptide set detected fewer 
responses and underestimated the breadth and the magnitude of responses within 
individuals, compared to the combined peptide sets from the three subtypes. 
Cross-subtype recognition for the 16 most frequently recognized peptides was 
identical only when the peptide sequences were invariant; in 9 of these 16 
peptides, diminished recognition was the result of subtype-related sequence 
variation, and a frame-of-epitope effect diminished or abrogated recognition in 4 
peptides. A minimal set of 15 frequently recognized Gag and Nef peptides was 
then designed and tested with cells from 50 HIV seropositive individuals and 
elicited responses in 47 of them, at a mean frequency of 715 SFC/106 peripheral 
blood mononuclear cells. Therefore incomplete cross-recognition between 
subtypes A, C, and D can be partially overcome using a defined peptide set 
representing frequently recognized epitopes, and potentially, by adjusting epitope 
frame within peptides.  These strategies can help to define optimal vaccine 
epitopes. 
 
In the third part of the present work, the Gag-specific CD8 T cell response of 
individuals infected with a single HIV strain was compared with the response 
observed in individuals infected with multiple HIV-1 strains. Breadth of Gag 
epitope recognition and cross-recognition of subtype-specific peptide pools was 
enhanced in multiply infected study subjects, whereas CD8 T cell recognition of 
Nef or Env appeared to be unaffected. Therefore the increased viral diversity in 
individuals infected with multiple HIV-1 strains affects the Gag-specific T cell 
response. As a consequence inclusion of multiple Gag variants in a HIV vaccine is 
likely to enhance vaccine-induced CD8 T cell responses and cross-recognition of 
HIV epitopes. 
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5. Zusammenfassung 
Es ist allgemein akzeptiert, daß die HLA Klasse I restringierte CD8 T Zellantwort 
bei der Kontrolle der Virusreplikation während einer HIV Infektion eine 
entscheidene Rolle spielt. Allerdings konnten nur wenige Studien eine Korrelation 
zwischen der HIV-spezifischen CD8 T Zellantwort und dem Krankheitsverlauf 
nachweisen. Der Krankheitsverlauf hängt von verschiedenen Faktoren ab, darunter 
die Viruslast nach der Primaervirämie, selten vorkommenden Mutationen in den 
HIV Korezeptorgenen, oder den HLA Klasse I Allelen. So geht beispielsweise die 
Expression bestimmter HLA Klasse I Allele mit einer niedrigen Plasma Viruslast 
einher. Eine Verbindung zwischen solchen “protektiven” HLA Klasse I Allelen 
und einer effizienten HIV-spezifischen CD8 T Zellantwort konnte jedoch bisher 
noch nicht nachgewiesen werden. Zur Beantwortung des zugrundeliegenden 
Mechanismus, der mit „protektiven“ HLA Allelen verbunden ist, wurden 53 HIV 
infizierte Frauen einer Hochrisikokohorte im Südwesten Tansanias bezüglich des 
HLA Typs, der Viruslast im Plasma und der CD4 T Zellzahl charakterisiert. 
Gleichzeitig wurde die Gag-, Nef- und Env-spezifische CD8 T Zell Antwort unter 
Verwendung eines Interferon gamma ELISPOT Assays bestimmt . 
 
Am häufigsten fanden sich in den Studienteilnehmerinnen CD8 T Zellantworten 
gegen Epitope in Gag und Nef, weniger häufig gegen Epitope in Env (Median: 3 
Gag, 2 Nef und 1 Env erkannte Epitope/Individuum). Die HLA Klasse I Allele 
B5801, B8101 und B0702 waren mit einer niedrigen Viruslast assoziiert. 
Gleichzeitig korrelierte die Expression von einem oder zwei dieser Allele mit einer 
breiteren Erkennung von Gag Epitopen (P =0,0035, Median:4 erkannte 
Epitope/Individuum) verglichen mit anderen HLA Klasse I Allelen (Median: 2 
erkannte Epitopen/Individuum). Die weitere Analyse der Gag-spezifischen CD8 T 
Zell Antwort offenbarte ein inverses lineares Verhätnis zwischen der Anzahl der 
erkannten Gag Epitope und der Viruslast im Plasma (R =-0,36 ; P = 0,0016). Des 
weiteren war die Erkennung von multiplen Epitopen in 2 Regionen des Gag 
Proteins (as001-as075 und as 248-500, GagR1R3) stark mit einer dauerhaften 
Kontrolle der Virusreplikation nach Serokonversion assoziiert. Zusammenfassend 
lassen diese Ergebnisse darauf schließen, daß die Erkennung multipler Epitope im 
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Gag Protein, ganz besonders in GagR1R3, wichtig für die Kontrolle der 
Virusreplikation während der chronischen Phase der HIV Infektion ist. 
 
Im zweiten Teil der vorliegenden Arbeit wurde die Erkennung von HIV-1 Subtyp 
A-, C- und D-spezifischen Gag und Nef Epitopvarianten durch CD8 T Zellen 
untersucht. 83% der Gag-spezifischen Epitopantworten wurden mit den Subtyp C 
Peptiden detektiert, während lediglich 51% und 57% der Gag-spezifischen 
Epitopantworten mit den Subtyp A beziehungsweise Subtyp D Peptiden detektiert 
wurden. Die erhöhte Frequenz Subtyp C-spezifischer Antworten könnte zum Teil 
mit dem vorherrschenden Vorkommen Subtyp C und Subtyp C-beinhaltenender 
rekombinanter HIV-I Stämme in Südwest Tanzania zusammenhängen. Dennoch 
würde die Anzahl der Gag-spezifischen Epitopantworten durch die ausschließliche 
Verwendung von Subtyp C-spezifischen Peptiden unterschätzt. Die Erkennung 
von Subtyp-spezifischen Peptidevarianten durch CD8 T Zellen war lediglich für 
Peptide gleicher Aminosäuresequenz identisch. Für 9 der 16 am häufigsten 
erkannten Peptide konnte eine abgeschwächte Erkennung von Varianten des 
selben Peptids mit Aminosäuresequenzunterschieden erklärt werden. Für 4 Peptide 
konnte eine abgeschwächte Erkennung von Peptidvarianten mit einer 
unterschiedlichen Positionierung des Epitops innerhalb der Peptidvarianten erklärt 
werden. Aufgrund dieser Ergebnisse wurde ein minimales Set aus 15 der am 
häufigsten erkannten Peptiden zusammengestellt Dieses bestand vor allem aus 
Subtyp C-spezifischen, aber auch aus Subtyp A- und D-spezifischen Peptiden und 
wurde anschließend mit peripheren mononuklären Blutzellen („peripheral blood 
mononuclear cells“, PMBC) von 50 HIV infizierten Personen auf Erkennung 
getestet. Dieser Peptidpool wurde mit einer durchschnittlichen Frequenz von 715 
SFC/106 PBMC von 47 dieser Personen erkannt. Zusammenfassend könnte diese 
Strategie dazu beitragen, optimale CD8 T Zell Epitopevarianten zu identifizieren, 
die in HIV Impfungen beinhaltet sein sollten. 
 
Im dritten Teil der vorliegenden Arbeit wurde die Gag-spezifische CD8 T Zell 
Antwort von Studienteilnehmerinnen verglichen, die mit einem oder mehreren 
verschiedenen HIV-1 Stämmen infiziert waren. Eine Mehrfachinfektion führt 
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dazu, daß mehr Gagepitope erkannten werden. Darüber hinaus war auch die 
gleichzeitige Erkennung von subtypspezifischen Peptiden in diesen 
Studienteilnehmerinnen besser ausgeprägt. Die Nef- und Env-spezifische CD8 T 
Zellantwort schien durch eine Mehrfachinfektion nicht beeinflusst.  
 
Für einen potentiellen HIV Impfstoff lässt sich aus der vorliegenden Arbeit 
schließen, daß es entscheidend sein kann, eine effiziente CD8 T Zellantwort zu 
induzieren. Vor allem sollten hierbei Gag-spezifische Epitopevarianten 
verschiedener Subtypen berücksichtigt werden.  
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